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Abstract
Generation of skeletal muscles with forms adapted to their function is essential for normal movement. Muscle shape is
patterned by the coordinated polarity of collectively migrating myoblasts. Constitutive inactivation of the protocadherin
gene Fat1 uncoupled individual myoblast polarity within chains, altering the shape of selective groups of muscles in the
shoulder and face. These shape abnormalities were followed by early onset regionalised muscle defects in adult Fat1-
deficient mice. Tissue-specific ablation of Fat1 driven by Pax3-cre reproduced muscle shape defects in limb but not face
muscles, indicating a cell-autonomous contribution of Fat1 in migrating muscle precursors. Strikingly, the topography of
muscle abnormalities caused by Fat1 loss-of-function resembles that of human patients with facioscapulohumeral
dystrophy (FSHD). FAT1 lies near the critical locus involved in causing FSHD, and Fat1 mutant mice also show retinal
vasculopathy, mimicking another symptom of FSHD, and showed abnormal inner ear patterning, predictive of deafness,
reminiscent of another burden of FSHD. Muscle-specific reduction of FAT1 expression and promoter silencing was observed
in foetal FSHD1 cases. CGH array-based studies identified deletion polymorphisms within a putative regulatory enhancer of
FAT1, predictive of tissue-specific depletion of FAT1 expression, which preferentially segregate with FSHD. Our study
identifies FAT1 as a critical determinant of muscle form, misregulation of which associates with FSHD.
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Introduction
Developmental genetics has provided considerable insight into
the regulatory networks controlling overall skeletal muscle
development. Perturbation of these common mechanisms is
associated with congenital abnormalities of the muscle lineage as
well as with later-onset muscle pathologies [1]. In contrast, less is
known about the mechanisms of functional diversification within
the muscle lineage. Such diversification may be either metabolic -
fast versus slow fibres, for example - or morphological, such as the
position and shape of individual muscles. Genes controlling
diversification too are likely to be of clinical significance [2–4],
since several human muscular dystrophies do not affect all muscles
evenly, but specifically target regionalized groups [5]. This is true
for limb girdle muscular dystrophy (LGMD), oculopharyngeal
muscular dystrophy (OPMD), myotonic dystrophies with oculo-
motor involvement, distal myopathies, scapuloperoneal dystrophy,
and facioscapulohumeral dystrophy (FSHD) [5–6]. In no case,
however, is the rationale for this geographic specificity currently
understood.
One characteristic example of focal myopathies is FSHD, which
affects subsets of muscles in the facial and shoulder areas [6]. The
main form of FSHD - FSHD1 - is an autosomal dominant disorder
associated with the contraction of an array of 3.3 Kb macro-
satellite repeats (D4Z4), located at the subtelomeric 4q35 locus [6].
The mechanism by which the D4Z4 contraction triggers the
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disease represents one of the most enigmatic conundrums for
human geneticists and remains incompletely understood. The
D4Z4 array has been suggested to act as an insulator between
telomeres and subtelomeric genes [7–8], such that its contraction
might result in regulatory changes in neighbouring genes that
could in turn alter muscle physiology [6,9–11]. Despite intense
focus on deregulated 4q35 genes, including one of the close
neighbours, FRG1 [12], and despite numerous large-scale inves-
tigations aimed at uncovering additional relevant candidates, none
of the genes reported accounts for all aspects of FSHD, and
additional players are still actively sought [6,9,13]. An emerging
model is that the pathogenic effect of D4Z4 contraction in FSHD1
is mediated in part by DUX4, a retrogene present within D4Z4
repeats themselves encoding a homeobox containing transcription
factor that is normally silent in muscle [14–15]. In FSHD1
patients, the contraction of the D4Z4 repeat array leads to a
change in chromatin structure that facilitates DUX4 expression
[16]. Furthermore, the pathogenicity of the D4Z4 contraction
requires polymorphisms distal to the last D4Z4 repeat, that create
a polyadenylation signal and thereby stabilize DUX4 mRNA [17].
This stabilized RNA thus leads to increased expression levels in
FSHD muscles of a pathogenic isoform of DUX4, which activity is
thought to be toxic for muscles through transcriptional activation
of various target genes including Pitx1 and p53 [18–21]. Another
less frequent form of FSHD, clinically identical to FSHD1, is
observed in absence of D4Z4 contraction. These cases, referred to
as contraction-independent FSHD, include cases called FSHD2,
that were shown to exhibit hypomethylated D4Z4 repeats, recently
shown to be caused by mutations in the SMCHD1 gene [22].
FSHD2 is caused by the combination of such SMCHD1 mutations
with a DUX4 permissive (polyA) context, and also leads to DUX4
overexpression [22]. While FSHD2 cases represent so far the
majority of contraction-independent cases, rare cases of contrac-
tion-independent FSHD with typical symptoms may also occur
without hypomethylation, and be caused by yet unidentified
pathogenic contexts. Neither the specificity of SMCHD1 or of
DUX4 expression nor of its target genes identified so far [18–
21,23–24], provide sufficient account for the specificity of the
muscle map and the non-muscular symptoms that characterize
FSHD.
The regional specificity in the map of muscles affected in FSHD
suggests that the causal abnormality interferes with a muscle
subtype-specific developmental process. A gene involved in
functional diversification during muscle development would thus
provide a logical candidate to fill this gap. We focused on the cell
adhesion molecule FAT1 because Fat-like protocadherins are
known modulators of the planar cell polarity (PCP) pathway [25–
27], a genetic cascade involved in coordinating tissue polarity,
morphogenetic movements, and polarized cell flow [28–30]. Fat1
has been reported to be expressed in developing muscles and
tendons [31] and to be regulated by muscle developmental genes
such as Pax3, Lbx1, or Met [32–34]. Thus, FAT1 may control
muscle shape through PCP-like mechanisms analogous to those
involved in polarized migration of vascular endothelial smooth
muscle cells [35].
Here, we report the unexpected finding that Fat1-deficient mice
reproduce the highly selective muscular and non-muscular aspects
of the clinical picture of FSHD. We show that Fat1 is required
during development to shape specific groups of shoulder and facial
muscles by modulating the polarity of myoblast migration. While
constitutive inactivation of Fat1 leads to neonatal lethality due to
defects in kidney development [36], Fat1 hypomorphic mice
exhibit defects of muscle integrity with a topography prefiguring
the map of muscles affected in FSHD. Furthermore, conditional
mutagenesis suggests that a cell-autonomous function of Fat1 in
migrating muscle cells may account for a significant part of its
muscle shaping function. The human FAT1 gene is located only
3.6 Mb from the critical FSHD genomic region at 4q35, and
emerges as a potential transcriptional target of DUX4 or p53
[18,37–38]. We present evidence of altered FAT1 levels in some
foetal FSHD1 cases, in muscle, but not brain, accompanied with
epigenetic modifications characteristic of silenced chromatin.
Finally, we identified genetic variants deleting variable lengths of
a putative cis-regulatory enhancer in the FAT1 locus, which
segregate with FSHD. Thus, either in presence or absence of
D4Z4 contractions, mechanisms leading to tissue-specific dereg-
ulation of FAT1 expression are associated with FSHD and may
contribute to causing regional-specific muscle shape abnormalities
that prefigure muscle degeneration in the adult.
Results
Fat1 regulates myoblast polarity during planar migration
In search of mechanisms that control muscle position and form,
we studied Fat1 expression at stages of muscle morphogenesis. We
chose first to study a muscle with a characteristic fan-shaped form,
the subcutaneous muscle cutaneous maximus (CM). During embryo-
genesis, following delamination from the dermomyotomal lip at
forelimb levels, CM precursors, identified through their specific
expression of GDNF, reach the base of the limb, turn, and spread
under the skin in a radial manner [39–40] (Figure 1A). This
migration pattern reflects collective and polarized cell migration,
visible owing to expression of the MLC3F2E reporter line or of the
muscle fate marker MyoD, through the formation of chains of
myoblasts aligned in radial directions (Figure 1B and 1E top right
panel). At the stages of CM migration, whole mount X-gal staining
in embryos carrying a LacZ reporter gene-trap insertion in the
mouse Fat1 gene revealed a hot-spot of Fat1 expression highlighting
the migration area (Figure 1C, Figure S1). We found that CM
myoblasts express Fat1 RNA and appear to be positioned in a
subcutaneous layer which itself expresses Fat1 RNA, this surround-
ing subcutaneous tissue displaying a rostrocaudal gradient of
Author Summary
Facioscapulohumeral muscular dystrophy (FSHD) is a
hereditary human myopathy affecting groups of skeletal
muscles in the face and shoulders. Despite recent
advances on the molecular cascade initiated by its main
genetic cause, with identification of DUX4 as the main
pathogenic agent, how this leads to the specific clinical
picture is still poorly understood. Here, we investigated the
role of the FAT1 protocadherin gene, located near the
FSHD locus, which was repressed by DUX4 in human
muscle cells. Disruption of the mouse Fat1 gene causes
muscular and non-muscular phenotypes highly reminis-
cent of FSHD symptoms. We show that Fat1 is required in
migrating muscle precursors, and that the altered muscle
shapes caused by Fat1 mutations are predictive of early
onset defects in muscle integrity in adult mutants, with a
topography matching the map of muscles affected in
FSHD. In humans, we observed FAT1 lowering in muscle
but not brain of foetal cases with canonical FSHD1, and
identified deletions of conserved elements in the FAT1
locus predictive of changes in FAT1 expression, that were
enriched among FSHD patients. Thus, deregulating Fat1 in
FSHD-related tissues provides a unique means to mimic
FSHD symptoms in mice and learn about pathogenesis of
this complex disease.
Deregulated FAT1 Expression as a Model of FSHD
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Figure 1. Fat1 controls the shape of subsets of scapular muscle by modulating myoblast polarity during planar migration. (A–C)
Reporter gene expression in the forelimb and flank of mouse embryos between E11.5 and E13.5. (A) Gdnf-lacZ staining labels myoblasts of the
latissimus dorsee (LD) and cutaneous maximus (CM). CM myoblasts migrate away from the brachial plexus to form a subcutaneous muscle sheath,
composed of radially-oriented chains of myoblasts. (B) At E13.5, MLC3f-lacZ staining reveals the characteristic fan-shaped form of the CM (dotted
white purple line) as compared to other limb muscles. (C) Fat1 expression detected using the lacZ gene trap allele KST249 (Fat1LacZ) is selectively
localized within the CM and in surrounding tissue (pink arrow). (D) CM myoblasts express Fat1 and migrate towards an increasing gradient of Fat1
expression. Alternate vibratome cross-sections of a wild type E12.5 embryo were hybridized with Fat1 (left column) and MyoD (purple, right column)
RNA probes. Photographs of adjacent sections were superimposed (photoshop) after conversion of Fat1 staining color in pink (right column; Fat1 in
pink, MyoD in purple). MyoD expression is used as a marker of the muscle lineage. Superimposition was meant to compare the relative levels of Fat1
expression within and around the cutaneous maximus (CM) muscle (indicated with purple arrows), at three consecutive antero-posterior positions,
respectively within the CM (top row), at the posterior end (middle row), and posterior to the caudal extremity of the CM at that stage. CM myoblasts,
migrating from anterior to posterior, express lower levels of Fat1 RNA than the surrounding subcutaneous cell layer (pink arrows). Intensity of Fat1
staining in this subcutaneous layer increases gradually in caudal sections. (E–H) Orientation of CM myoblast migration in whole-mounts of E12.5
Fat1LacZ/LacZ and control embryos detected using MyoD in situ hybridization. In all panels anterior is to the left, dorsal is to the top. (E) The CM muscle
Deregulated FAT1 Expression as a Model of FSHD
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intensity, with highest intensity caudal to the extremity of the CM
(Figure 1C; D). Thus, CM myoblasts express Fat1 and appear to
migrate along an increasing gradient of Fat1 expression.
We therefore asked whether Fat1 was required for CM location
and/or form. We first took advantage of a mouse model carrying a
gene-trap insertion in the mouse Fat1 gene [41–42] (allele referred
to as Fat1LacZ). Initial differentiation along the muscle lineage was
unaffected in Fat1LacZ/LacZ embryos since CM myoblasts retained
expression of broadly-expressed markers such as MyoD (n = 6), and
markers of subsets of myoblasts (such as Six1 (n = 2), gdnf (n = 2),
and Lbx1 (n = 2); data not shown). This allowed us to use MyoD
expression to monitor precursor migration in Fat1 mutants. In
E12.5 Fat1LacZ/LacZ embryos, we observed 1) an aberrant
morphology of the CM muscle, reduced in size, and with ill-
defined anterior limits (Figure 1E), 2) a dispersion of migrating
myoblasts not only within the CM but also in ectopic areas
traditionally devoid of muscle cells. In the CM, higher magnifi-
cation observations revealed that migration myoblasts failed to
show a preferential alignment of their nuclei into migratory chains
(Figure 1E–H). This phenotype was associated with morphological
changes in individual myoblasts, such as the loss of long
cytoplasmic protrusions extending from the leading edge and
rounded morphology of some nuclei within the chains (Figure 1G,
H). In further support of a role for Fat1 in migration polarity,
numerous clusters of ectopic myoblasts or disoriented single
myoblasts were found in the shoulder region of E12.5 mutants,
either in ectopic places, or within additional shoulder muscles such
as the spinotrapezius muscle (Figure 1E orange arrowheads in
orange dotted area; Figure S2, red arrows).
Regulation of myoblast polarity requires FAT1
transmembrane domain
Further genetic evidence of such a function of FAT1 in control
of muscle shape was obtained with another targeted allele of the
Fat1 locus, which we engineered by flanking two exons, 24 and 25,
the latter containing the transmembrane domain, with LoxP sites
(Figure S3A, targeted allele referred to as Fat1Fln). Crossing of mice
carrying the conditional Fat1Fln allele with a ubiquitous CRE-
expressing mouse line produced, by germline excision of the floxed
exons, a constitutively recombined allele, Fat1DTM, which encodes
FAT1 protein isoforms lacking the corresponding transmembrane
domain (Figure 2A,B). Analysis of myogenic differentiation by in
situ hybridization with a myoD probe indicated that Fat1DTM/DTM
embryos exhibited phenotypes identical to those seen in
Fat1LacZ/LacZ embryos (data not shown). This new allele also
allowed studying later steps of muscle differentiation by crossing
Fat1DTM mice with a transgenic line in which nls-LacZ reporter
activity is driven by an enhancer from the mlc3f gene (MLC3F-2E)
[43]. Expression of this transgene (MLC3F-2E:LacZ) is detected
slightly later than myoD expression as it reflects differentiation in
myocytes and sarcomere assembly [43], hence it allows visualising
muscle shapes, but not migrating myoblasts. MLC3f-2E expression
in Fat1DTM/DTM embryos revealed again the altered morphology
of the CM muscle, with missoriented chains of myocytes in the
ventral/pectoral half of the CM and shoulder belt muscles
(Figure 2D, and Figure S3B). Furthermore, Fat1DTM/DTM embryos
were found to exhibit an extra muscle ectopically located in the
shoulder area (Figure 2D). Finally, we also visualized multinucle-
ated myofibres owing to the nuclear b-galactosidase staining at late
gestation stages, and confirmed the persistence of misoriented
myofibers in the mature CM muscle of Fat1DTM/DTM E18.5/P0
embryos (Figure 2D). Taken together, our data show that Fat1 is
required to control the shape and position of subsets of migratory
muscles in the developing embryo, by controlling coordinated
polarity of collectively migrating myoblasts.
The developmental map of Fat1-dependent muscles
We next wished to extend our description of the map of Fat1-
dependent muscles by exploring the phenotypes exhibited by
Fat1DTM/DTM embryos carrying the MLC3F-2E transgene at later
developmental stages (E14.5 and E15.5), when migration has been
completed and muscle shapes are determined. In the scapulohu-
meral area of all Fat1DTM/DTM;MLC3F-2E embryos examined, we
consistently observed an extra muscle in a stereotyped ectopic
position, systematically attached between the spinodeltoid muscle
and the triceps brachii muscles (Figure 3A,B). Just dorsal to the
spinodeltoid, we found a subcutaneous portion of the spinotrapezius
muscle (SpTS) to be drastically reduced in Fat1DTM/DTM;MLC3F-2E
embryos (Figure 3A, orange arrows). Observation from a dorsal
point of view reveals that midline junction of the CMmuscle and of
Rhomboid muscles (Rh) is delayed, so that a large gap is seen in the
back of an E14.5 Fat1DTM/DTM embryo (Figure 3B, orange line).
Numerous mispositionned myofibres create ectopic bridges
between the acromiotrapezius and spinotrapezius muscles in
Fat1DTM/DTM;MLC3F-2E embryos (Figure 3B; read arrows in top
and middle picture). Analysis of muscles in the face at E14.5, E15.5,
and at P0, reveals abnormalities in shape, myofibre orientation, and
density in several subcutaneous muscles in the facial skin (Figure 3C,
red arrows) that occupy positions reminiscent of the position of
human muscles of facial expression. The flat structure of these
subcutaneous muscles is analogous to that of the CM muscle, and
the alterations observed in Fat1DTM/DTM neonates also include
random orientation of multinucleated myofibres (Figure 3C). In
contrast, deeper muscles such as the masseters display normal shape
in Fat1DTM/DTM mutants (see Figure 3C and data not shown). Of
notice, although muscle shape defects were found in stereotyped
places, their severity was variable, and Fat1DTM/DTM embryos were
frequently asymmetrically affected (Figure S4, see also Figure
S12A). As previously observed in Fat1LacZ/LacZmutants, examination
of muscle development at E14.5 and E15.5 in Fat1DTM/DTM
embryos confirmed that Fat1 loss of function selectively affects
muscles of the facial and scapulohumeral ares, and that Fat1 is not
required to shape other migratory muscles such as the diaphragm or
hindlimb muscles, which were identical between wild type and
Fat1DTM/DTM embryos (Figure S4 and data not shown). Overall, in
addition to the abnormal shape of the cutaneous maximus muscle,
we found that Fat1 was required to shape selective and stereotyped
groups of muscles in the scapulohumeral interface, as well as
subcutaneous muscles of the face.
(purple dotted line) in Fat1LacZ/LacZ embryos displays reduced size and altered shape as compared to wild type. Higher magnification images (right
hand panels) show that within the CM muscle, radial organization of myoblast chains was perturbed by Fat1-deficiency, resulting in a fuzzy migration
front and irregular distribution of myoblasts (red arrows). In addition, ectopic clusters of myoblasts (orange arrows) are detected in the shoulder area
(dotted orange line). (F) Quantification of the abnormal orientation of Fat1 mutant myoblasts. The angle between the longest diameter of each
myoblast nucleus and the axis of the closest myoblast chain was measured on flat-mounted CM muscles. The bar graph presents mean (6 s.e.m.)
percentages of myoD+ nuclei displaying a given angle (by angle ranges of 10u) for wild type (gray) and Fat1LacZ/LacZ (black) embryos. (G, H) High
magnification images of MyoD-expressing myoblasts in equivalent positions – within the chains (G) or at the leading edge (migration front, H) – in
the CM of mutants and controls. Scale bars: (A–C), 0.8 mm; (D) 300 mm; (E), left: 0.5 mm; (E), right: 100 mm; (G, H) 10 mm.
doi:10.1371/journal.pgen.1003550.g001
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Mice with reduced Fat1 expression develop early
regionalized muscle wasting restricted to mis-shaped
muscles
We next asked what the consequences of these muscle shape
abnormalities were at postnatal stages. Constitutive deletion of
Fat1 was initially shown to lead to neonatal lethality most likely
due to defects in kidney filtration [36,42]. Likewise, constitutive
deletion of the transmembrane domain (Fat1DTM/DTM mice) also
leads to more than 50% lethality at birth, with only a small
proportion of mutants surviving to adulthood (Figure S3C). We
chose to examine adult Fat1LacZ/LacZ mutants, since the hypomor-
phic Fat1LacZ allele, which results from an insertion of a gene-trap
construct in an intron, not deleting any functional domain, allows
expression of variable amounts of residual Fat1 RNA and FAT1
protein in Fat1LacZ/LacZ mutants (Figure 2E, Figures S5, and S13).
This hypomorphic allele, in the genetic background we used,
allowed bypassing the neonatal lethality in Fat1LacZ/LacZ mutants,
with more than half the mutant mice surviving after 3 months
(Figure 4C), and enabled us to study the postnatal consequences of
reduced Fat1 levels. The variable amounts of residual Fat1
correlates with the variability in the severity of phenotypes and
in the age of death of Fat1LacZ/LacZ mice. A fraction of these adult
phenotypes, in particular the lethality, is likely to result from
systemic consequences of kidney phenotype. Indeed, analysis of
kidney morphology in the subset of Fat1LacZ/LacZ mice that
exhibited severe weight loss revealed features characteristic of
polycystic kidneys, such as cysts formed of enlarged tubules in the
cortical renal area (data not shown). Therefore, to score with an
objective criterion the progression through adult phenotype stages,
Figure 2. The transmembrane domain of FAT1 is required to polarize muscle migration. (A) Schemes representing the main protein
product expected from a wild type, a Fat1LacZ, and a Fat1DTM locus. Positions of the epitopes for three antibodies are also shown, with a color code
matching that used in the western blots below. (B) Western blot analysis of the FAT1 protein products observed in total lysates from E12.5
Fat1LacZ/LacZ, wild type, and Fat1DTM/DTM embryos using indicated antibodies, which targeted epitopes are positioned in (A). (C) Whole mount LacZ
staining of E12.5 Fat1LacZ/LacZ mutant embryo. (D) Skeletal muscle groups were visualized in E12.5, E13.5, and E18.5 control and Fat1DTM/DTM embryos
carrying the MLC3f-2E transgene, by X-gal staining. Whole mount analysis of skeletal muscles confirms the presence of a reduced CM (red dotted
lines) at E12.5, leading to a misshaped CM one day later (E13.5), and the systematic presence of ectopic muscles in the shoulder area (yellow arrow),
most frequently inserting between the deltoid and triceps muscles. Flat mounted preparations of the CM dissected from an E18.5 Fat1DTM/DTM
embryo, showing the reduced density as well as randomly oriented multinucleated myofibres (right panels). (E) Whole mount in situ hybridization on
E10.5 embryos with an RNA probe matching the Floxed exons (exons 24–25, the probe is indicated in yellow in Figure S4A). The profile of Fat1 RNA
expression in a wild type embryo matches previously reported expression domain, including staining in the limb, somites, branchial arches,
telencephalon, midbrain, eye, tail bud, and neural tube roof plate. Fat1DTM/DTM embryos are entirely devoid of staining, apart from the otic vesicle, a
known site of substrate trapping (yielding background staining). In contrast, varying amounts of residual RNA were consistently observed in
Fat1LacZ/LacZ embryos, in the telencephalon, midbrain, limbs, tailbud, and somites. Two examples are shown with different RNA levels detected.
doi:10.1371/journal.pgen.1003550.g002
Deregulated FAT1 Expression as a Model of FSHD
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body weight was measured for each individual and compared to its
own maximal weight [44]. We arbitrarily set the moment a
Fat1LacZ/LacZ mutant mouse has lost 10% of its weight as the visible
onset of symptoms associated with kidney malfunction or with
other phenotypes likely to have systemic consequences. Mutant
mice showing more than 10% loss at the stage of analysis were
defined as ‘‘symptomatic’’ (related to generalized symptoms, and
not to muscles only), and the degree of severity was recorded as
percentage weight loss, while Fat1LacZ/LacZ mutant mice that did
not exhibit any weight loss yet were defined as presymptomatic.
Figure 3. Fat1 loss of function alters shapes of selective facial and scapulohumeral muscles. Skeletal muscle groups were visualized in
E14.5, E15.5, and E18.5 wild type and Fat1DTM/DTM embryos carrying the MLC3f-2E (LacZ) transgene, by X-gal staining. (A) overview of the face and
forelimb musculature at E14.5. Overall, constitutive ablation of Fat1 causes developmental abnormalities of muscle shape, affecting selective
subcutaneous muscles in the face (Zyg. Min and Zyg maj, muscles, Occip. F, orbic. Or. and temporalis Muscles) and selective muscles in the
scapulohumeral region. Muscle names are indicated. Muscles which are reduced or show an altered shape have their name underlined in Fat1DTM/DTM
mutant pictures. Ectopic muscles are indicated with red arrows. (B) Muscles of the scapulohumeral area at E14.5 and E15.5, visualized with dorsal
views of the scapular muscles at E14.5, and side views of the forelimb at E15.5. Dorsal views reveal the reduced extent of the CM and Rhomboid
muscles, and the abnormal connections between the upper and lower parts of the trapezius (amT and spT, respectively). A large additional ectopic
muscle (red dotted line, bottom picture) is observed in Fat1DTM/DTM embryo, that appears ectopically inserted between the spinodeltoid and Triceps
brachii (LoTB and LaTb) muscles. (C) Analysis of muscles in the face at E14.5 (A), E15.5 (C, top), and at P0 (C, bottom), reveals abnormalities in shape,
myofibre orientation and density in several subcutaneous muscles (red arrows) that occupy positions equivalent to that of human muscles of facial
expression, while deeper muscles such as the masseters (see Figure 6D and data not shown) display normal shape. Overall the topography of muscles
affected in Fat1 mutant mice resembles the map of muscles affected in human FSHD muscle in early phases of the disease. Muscle names
abbreviations: amT: acromiotrapezius; amd: acromiodeltoid; Bra: brachialis; CM: cutaneous maximus; Ecu: Extensor carpi ulnaris; Ecr: Extensor carpi
radialis; Edc: Extensor digitorum communis; Edl: extensor digitorum longus; Fr: Frontalis; LaTb: lateral Triceps Brachii; LoTb: Longitudinal Triceps
Brachii; Occ: occipitalis; Orbic. Oc: orbicularis oculis; Orbic Or: Orbicularis Oris; Risor: Risorius (position equivalent to that of Risorius in human); SpD:
spinodeltoid; SpT: spinotrapezius; SpTS: Subcutaneous part of the Spinotrapezius muscle; Temp: Temporo-parietal muscle; Zyg: Zygomaticus
(position inferred from equivalent position in human).
doi:10.1371/journal.pgen.1003550.g003
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Although this threshold of 10% weight loss was defined arbitrarily,
and even though we cannot exclude that kidney phenotypes also
have systemic consequences earlier than this limit, it is difficult,
during symptomatic phase, to attribute a primary cause to the
symptoms observed. We therefore focused on the presymptomatic
phase for most of our studies of adult muscle, and also chose to
exclude from our adult studies mutant mice with an impaired
growth curve. While Fat1LacZ/LacZ mice at symptomatic stages (with
20–30% body weight loss) displayed generalized muscle mass
reduction (Figures S6B–C, presymptomatic mutant mice showed
scapular winging, whereas lumbar posture and hindlimb function
appeared unaffected (Figure 4A). Postural abnormalities affecting
the shoulder area, indicating weakness of the muscles involved in
scapular movements, can be seen when presymptomatic mice
move on a cage grid, especially in situations in which they
challenge the shoulder girdle muscles by transferring bodyweight
rostrally on their forelimbs. These postural abnormalities were
accompanied by functional motor defects evidenced in rotarod
assays at presymptomatic stages (Figure 4E). Early symptomatic
mice (around the 10% threshold) also showed kyphosis, a
curvature of the spine known as a hallmark of muscle wasting in
the shoulder girdle (Figure 4D, F), without displaying skeletal
abnormalities (Figure 4B, X-ray). Similar observations were made
in the small proportion of Fat1DTM/DTM mice that survived to adult
stages.
We next investigated the pathological basis for the selective
postural abnormality of the scapulae at presymptomatic stages.
Dissection of individual muscles in presymptomatic Fat1LacZ/LacZ
mice revealed a significant mass reduction for both rhomboid
muscles when compared to controls (Figure 4D). As expected from
the embryonic defect, a severe reduction in thickness of the CM
muscle was also observed, although its subcutaneous location
made accurate dissection and therefore mass measurement
unfeasible. Defects in myofibre orientation similar to those
observed at late embryonic stages were confirmed in CM (Figure
S6D and data not shown) and in rhomboid muscles (Figure 4G) at
all stages examined. In contrast, masses of muscles with unaltered
shape when examined during development (i.e hindlimb muscles
such as gastrocnemius or soleus) were also not significantly
reduced at presymptomatic stages (Figure 4D, Figure S6B, S7).
This argues that persistence in mature muscles of misoriented
myofibres resulting from fusion of depolarized myoblasts contrib-
utes to the shoulder muscle phenotype in presymptomatic mice,
although it does not rule out an additional direct function of Fat1
in muscle, whose loss may also cause muscle degeneration. Lastly,
another consequence of developmental dysgenesis that is likely to
contribute to focal muscle wasting is the persistence of ectopic
muscles (Figure S7). Such ectopic muscles were found to share
tendon attachment sites with existing muscles (typically two
ipsilateral muscles) including shoulder belt muscles (trapezius,
LD, pectoral muscles), and the humeral muscle triceps brachii
(Figure S7). This association correlated with a unilateral reduction
of the corresponding muscle mass, reduction that nevertheless did
not result significant until early symptomatic stages (Figure 4D and
data not shown).
The phenotypes resulting from developmental dysgenesis were
not restricted to muscle shape and mass. Histological analyses
revealed that a significant reduction in fibre diameter was
detectable already at early symptomatic stages in those muscles
in which we detected developmental defects, including the CM,
Rhomboids (Figure 4G, superior and profundis), and Trapezius
muscle (Figure 5C, pooled analysis). This was also true for
Fat1DTM/DTM mice analysed at presymptomatic stages (Figure S8).
In contrast, at presymptomatic stages, analysis of myofiber
diameters in muscles whose shape was unaffected at developmen-
tal stages (such as gastrocnemius or soleus, and also diaphragm)
revealed no significant abnormality as compared to control mice
(Figure 4D, Figure S6B, and data not shown). In affected muscles
(trapezius, rhomboid, Pectoralis Major, LD, and CM), we
observed a range of additional abnormalities including inflamma-
tory infiltrations between myofibres, most frequently perivascular,
in both presymptomatic Fat1LacZ/LacZ and Fat1DTM/DTM mice
(Figure S6D and Figure S7). Fibre necrosis was also observed at
more advanced symptomatic stages (beyond 10% weight loss,
Figure S7L and data not shown), but as mentioned earlier, it is
impossible to distinguish whether any abnormality at symptomatic
stage is strictly related to muscle defects, or reflects systemic
consequences of unrelated phenotypes. Finally, observation of
myofibre structure in affected muscles (trapezius, rhomboid,
Pectoralis Major, LD, and CM) revealed progressive disruption
of higher level organization, with appearance at presymptomatic
stages of multiple faults disrupting the regular alignment of
sarcomeric structures (Figure 5A, D), and the detachment of the
sarcolemma from the contractile apparatus (Figure 5D). Overall,
alterations of muscle integrity at pre-symptomatic stages were only
detected in those muscles in which we reported fully penetrant
myoblast or myofibre orientation defects (CM, Rhomboids, and
Tapezius). Analysis of neuromuscular junctions in affected
shoulder muscles also revealed a proportion of junctions showing
fragmentation (Figure 5B), denervation, and atrophy (Figure S9).
Such defects did not reflect a primary failure of NMJ innervations,
as all neuromuscular junctions observed at early postnatal stages
(P3) were indistinguishable from wild type (data not shown).
Nevertheless, although the muscles that were spared during
development and at presymptomatic stages (e.g gastrocnemius,
soleus, masseters) were seen to harbour histological signs of muscle
atrophy (evenly reduced myofiber diameter) at advanced symp-
tomatic stages (Figure S6B), we did not observe muscle degener-
ation, inflammation, necrosis, or fragmentation of the contractile
apparatus (data not shown). These results are consistent with the
possibility that the developmental abnormalities of muscle shape
constitute a topographic frame in which muscles might be
predisposed to undergo early onset muscle wasting, prior to the
appearance of systemic consequences of non-muscle phenotypes
and the concomitant generalization of muscle wasting. These
findings do not exclude however the possibility that Fat1 may play
additional roles during muscle biology other than controlling
shape during development.
Ablation of Fat1 functions in premigratory myoblasts
with Pax3-cre is sufficient to alter muscle shape
We next asked if the function of Fat1 in shaping facioscapulo-
humeral muscles was exerted cell-autonomously in migrating
muscle precursors. In order to perform tissue-specific ablation of
Fat1 in muscles at a stage compatible with migration, we reasoned
that transgenic lines in which CRE expression would reproduce
that of genes of the muscle differentiation cascade, such as myoD or
Myf5, would occur too late to have an impact on the migration
itself. Therefore, to ablate Fat1 exons 24 and 25 in premigratory
myoblasts, we took advantage of the Pax3-cre knock-in line [45]
(Figure S10). Our conditional allele of Fat1 (Fat1Fln) initially
includes the neo cassette that was used to engineer the mouse
model. Although presence the neo cassette caused mild lowering of
Fat1 expression levels (Figure S11), this only resulted in subtle,
although statistically significant, morphological defects in
Fat1Fln/Fln embryos/mice compared to controls (Figure 6 and
Figure S12). This allowed using the Fat1Fln/Fln mutants for
conditional studies with tissue-specific CRE lines, without
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Figure 4. Presymptomatic adult Fat1 mutant mice show selective defects in scapular muscles. (A) Adult Fat1LacZ/LacZ mice show visible
scapular winging (orange arrow) at stages prior to detectable weight loss (defined as presymptomatic). Pictures (extracted from movies) show a
posture in which the mice challenge their shoulder girdle muscles by extending their head as far rostral as possible. At 7 weeks, wasting of the
rhomboid muscles can already be detected in presymptomatic Fat1LacZ/LacZ mice as they move on a cage grid. Note the large gap (orange arrow)
between scapulas (where rhomboids normally maintain scapulas attached to the dorsal spine), not visible in the corresponding position in the wild
type littermate. (B) At advanced symptomatic stages (30% weight loss, anesthetized mice), there is marked curvature of the spine in the upper back
and shoulder area, also visible through X-ray post-mortem imaging. (C) Kaplan-Meier plot showing survival of wild type, Fat1LacZ/+, and Fat1LacZ/LacZ
mice. Most Fat1LacZ/LacZ mice die between 2 and 4 months, with a median survival of 3 months, while a small group survives beyond 6 months. (D)
Masses of dissected muscles of Fat1LacZ/LacZ mice at presymptomatic disease stage (0% weight loss, n = 3) relative to age-matched controls (n = 6;
average wild type weight defined as 100%). (E) Motor performance defects in presymptomatic adult Fat1LacZ/LacZ mice. Rotarod analysis shows that
the latency to fall off from the rod was significantly shorter in presymptomatic adult Fat1LacZ/LacZ. In this set of experiments, additional Fat1LacZ/LacZ
mice that were symptomatic at the stage when training started had died by the time the test was performed and are therefore not included in the
graph. (F) Scapular muscle dissection in adult wild type and Fat1LacZ/LacZ mice reveals a pronounced reduction in volume and thickness of the
rhomboid superficialis (Rh. Sup.) and rhomboid profundus (Rb. P.). This likely underlies the scapular winging phenotype. In the top pictures, the
trapezius cervicalis (Trap) has been removed on the right side of each mouse to uncover the other scapular muscles (rhomboids: Rho; levator scapula:
LS). Yellow dotted lines indicate the extent of the scapula, red and orange dotted lines that of the two rhomboid muscles. The intermediate
magnification highlights the respective shapes of the rhomboid superficialis (orange dotted line) and rhomboid profundus (purple dotted line). (G)
Phalloidin staining of flat-mounted rhomboid superficialis muscles of wild type and Fat1LacZ/LacZ mice at presymptomatic (middle panel) or advanced
disease (20% weight loss; bottom panel) stages shows that early defects of myofiber orientation precede reduction of myofibre diameter. Scale bars:
(F) 2 mm; (G) 300 mm.
doi:10.1371/journal.pgen.1003550.g004
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requiring Flp/FRT recombination to further ablate the neo
cassette. We therefore compared muscle development in Fat1Fln/Fln;
Pax3cre/+ and Fat1Fln/Fln embryos, taking advantage of the
MLC3F-2E transgene 1) to visualize the shape of every muscle
and 2) to quantify the number of muscle cells dispersed in ectopic
areas. We followed muscles belonging to Pax3-derived territories in
the scapulohumeral area, where ablation of Fat1 leads to
measurable phenotypes in Fat1DTM/DTM;MLC3F-2E+ embryos
(Figure 6A). First, we found significantly higher numbers of
dispersed myocytes in the forelimb of Fat1Fln/Fln;Pax3cre/+ embryos
than in Fat1Fln/Fln embryos (Figure 6A, B). Second, an ectopic
muscle similar to the one found in Fat1DTM/DTM embryos could be
measured in Fat1Fln/Fln;Pax3cre/+ embryos, and its surface was
significantly larger than in Fat1Fln/Fln embryos (Figure 6A, C). At
later developmental stages, in addition to confirming the persistence
and position of this ectopic muscle in Fat1Fln/Fln;Pax3cre/+ embryos,
as in Fat1DTM/DTM; MLC3F-2E+ embryo. Furthermore we also
detected a reduced density of myofibers in the CM muscle and in
Figure 5. Abnormally shaped shoulder muscles of Fat1-deficient mice develop phenotypes involving reduced muscle fibres
diameter and structural abnormalities. (A) Muscle architecture visualized on transverse (A1,2) or longitudinal (A3–6) sections of rhomboid
muscles from wild type and Fat1LacZ/LacZ mice (20% weight loss), using antibodies against laminin and a-actinin, or toluidine blue staining. (B) NMJs
were visualized by immunolabeling nerve endings with anti-neurofilaments antibodies (NF, red) and AchR clusters with a-bungarotoxin (green). (C)
Plot of muscle fiber diameter in scapular muscles (rhomboid, trapezius, latissimus dorsi, and cutaneous maximus) of adult Fat1LacZ/LacZ mice at early
symptomatic (n = 5, red bars) and advance stages (n = 7, green bars), compared to wild type littermates (n = 12, blue bars). (D) Electron micrographs
at three different magnifications in rhomboid muscle fibres from Fat1LacZ/LacZ adult mice at early symptomatic stages (6–15% weight loss) show
fragmentation of the myofibre architecture and loss of t-tubule integrity. In wild type myofibres, t-tubules (purple arrows) are visible between
myofibrils, precisely aligned on either side of each Z-band, at a position coinciding with the end of the myosin filaments. By contrast, in dystrophic
fibres from Fat1LacZ/LacZ mice, the general disorganization correlated with missing (stars), mis-oriented, mis-aligned (orange arrows), or fragmented
(red arrows) triads. An increased distance (indicated as blue double arrowed bar) between the sarcolemma and contractile apparatus is observed in
Fat1LacZ/LacZ muscles, compared to wild types, indicating a loss of the tight association between the contractile apparatus and the sarcolemma. Scale
bars: (A1–2) 50 mm; (A3–6) 20 mm; (B) 15 mm; (D1,2) 5 mm; (D3,4) 0.5 mm; (D5,6) 0.2 mm.
doi:10.1371/journal.pgen.1003550.g005
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the subcutaneous part of the spinotrapezoid muscle (Figure S12). As
the Pax3cre/+ line is a CRE knock-in, but also a knock-out of the
endogenous Pax3 locus, the resulting loss of one copy of Pax3may be
in itself sufficient to enhance FAT1-dependent phenotypes. To rule
this out, we have evaluated the effect of combining a Pax3cre/+
context to the recombined Fat1DTM allele, and found no enhanced
phenotype in either Fat1DTM/+:Pax3cre/+ or Fat1DTM/DTM:Pax3cre/+
embryos compared to Fat1DTM/+ or Fat1DTM/DTM embryos,
respectively (data not shown). Finally, Fat1Fln/Fln;Pax3cre/+ embryos
did not display significantly more abnormalities in the subcutaneous
facial muscles or in the spinotrapezius muscle than the mild
phenotypes observed in Fat1Fln/Fln embryos (Figure S12), consistent
with the fact that facial muscles do not belong to the Pax3-CRE
lineage [46]. Furthermore, if ablation in facial neural crest cells,
driven by Pax3-CRE activity, had been responsible for altering
muscle shape, it would have done so as efficiently in facial muscles as
in trunk muscles. The lack of enhancement of facial muscle
phenotypes in Fat1Fln/Fln;Pax3cre/+ compared to Fat1Fln/Fln embryos
thereby also excludes a contributing role of Fat1 expression in neural
crest-derived cells. Thus ablating Fat1 in Pax3-derived cells is
Figure 6. Ablation of Fat1 in premigratory myoblasts using Pax3-cre partially reproduces the muscle migration/shape abnormalities
of the constitutive knockout. (A) Skeletal muscle cells were visualized at E12.5 in WT, Fat1DTM/DTM, Fat1Fln/Fln, and Fat1Fln/Fln; Pax3cre/+ embryos,
owing to the MLC3F-2E transgene by performing X-gal staining, after clearing in 100% glycerol. The upper panels show micrographs of the forelimb
area, and indicate the positions at which higher magnification pictures shown in the two lower panels were taken. (B, C) The phenotype was
quantified in WT, Fat1DTM/DTM, Fat1Fln/Fln, and Fat1Fln/Fln; Pax3cre/+ as well as in the control genotypes in Fat1DTM/+, Fat1Fln/+ and Fat1Fln/+; Pax3cre/+ and
Pax3cre/+ in two different manners: (B) by counting the number of dispersed myocytes found in the elbow area (orange dotted lines in the lower
panels in (A)), (C) by measuring the area occupied by the ectopically positioned muscle (or myocyte cluster) that appears inserted between (red
dotted line in middle panels). All data from a given genotype are plotted on a vertical line. Overlapping dots were arbitrarily moved away from the
vertical lines to allow showing all results distinctly. In both cases, the Fat1DTM/DTM, Fat1Fln/Fln, and Fat1Fln/Fln; Pax3cre/+ groups were each significantly
different from the control genotypes (WT, Fat1Fln/+, and Fat1Fln/+; Pax3cre/+ respectively, t-test, p values indicated), and were significantly different from
each other (Fat1DTM/DTM from Fat1Fln/Fln, and from Fat1Fln/Fln; Pax3cre/+, but also Fat1Fln/Fln from Fat1Fln/Fln;Pax3cre/+, t-test, p values indicated).
doi:10.1371/journal.pgen.1003550.g006
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sufficient to partially reproduce the defects observed in scapulohu-
meral muscles of the constitutive Fat1 mutants, indicating that Fat1
is required cell-autonomously in migrating myoblasts to control the
polarity of their migration.
Later FAT1 expression in differentiated muscles
As we asked whether in addition to the control of muscle
migration, Fat1 may play additional roles in mature muscle, we
noticed that in mouse, Fat1 is also expressed in differentiated
muscle fibres after migration stages. This expression can be
detected through the pattern of b-galactosidase expression in
Fat1LacZ/+ embryos, and by in situ hybridization (Figure 7A).
Furthermore antibodies against FAT1 C-terminal cytoplasmic tail
detected a protein localized in stripes within muscle fibres
(Figure 7B–D), on either side of alpha-actinin-positive sarcomere
boundaries (so called Z-bands, Figure 7B). In adult mouse muscle,
the stripes of FAT1 protein are closely juxtaposed with DHPR, a
calcium channel present in transverse (t)-tubules [47] (Figure 7B).
Such localization is consistent with Fat1 also playing a direct role
in muscle biology, distinct from its early function in orienting
myoblast polarity. Consistent with previous reports showing that
cytoplasmic variants in FAT1 proteins exhibit distinct subcellular
localisation [48], and that the cytoplasmic domain can translocate
in the nucleus [49], another antibody directed against the
cytoplasmic domain (FAT1-1465 antibody) also detected FAT1
protein in significant proportion of nuclei in adult mouse muscle
fibres (data not shown). Western blot analyses indicated that a full
length FAT1 protein is only detected in whole embryo extracts (at
E12.5, Figure 2B) or in isolated brain tissue, but not in muscle
tissue, where the most abundant bands detected with anti-FAT1-
ICD antibodies were smaller molecular weight proteins (Figure
S13), which production is spared by the genetic alterations in both
Fat1LacZ/LacZ and Fat1DTM/DTM mutants (Figure 7C,D, Figure S5,
S11, S13 and data not shown). While some of these smaller
isoforms might be cleavage products of full length FAT1 [50–52],
additional short isoforms are also consistent with gene products
resulting from transcript initiation at alternative downstream
promoters, as proposed by genome browsers (Ensembl, UCSC;
Figure S5A, with EST-based genes referenced in NCBIM37
mouse genome and in GRCh37 human genome assemblies).
Neither the gene trap insertion after the first exon (this study), nor
the removal of the entire first exon (in the published knockout
allele [36]), suppress such gene products. Deletion of the
transmembrane domain in Fat1DTM/DTM mutants also allowed
expression of protein products with unchanged size (Figure S13),
although it nevertheless led to a more severe phenotype with
drastic neonatal lethality (compare Figure S3C and Figure 4C).
Quantitative RT-PCR confirmed the presence of significant
amounts of Fat1 RNA containing the last exons (26 to 28) in
Fat1DTM/DTM mutants, albeit at reduced levels when compared to
wild types (Figure S11). Thus, in the case of all mutant alleles, the
remaining smaller isoforms might still carry out Fat1 functions at
least partially, resulting in hypomorphic phenotypes with variable
Figure 7. Fat1 expression at late stages of muscle differentiation. (A) Fat1 expression was visualized in E13.5 embryos or in neonate (P0)
muscle by b-galactosidase staining or by in situ hybridization with a Fat1 39UTR RNA probe. (B–D) Immunolocalization of FAT1 (anti-FAT1-ICD from
[35], green) was performed in E12.5 mouse embryo (C), and on adult (B, D) muscle fibers on longitudinal muscle cryosections from wild type (B, C1–3,
D1,4), from Fat1
DTM/DTM embryos (C4–6), and from Fat1
LacZ/LacZ (D2–3, D5–6) mice, combined with either antibodies against alpha-actinin (red, B5),
DHPR (Cacna1s) (red, B2,3), or RyR (red, B4), or with Phalloidin (red, C, D). In D, Green channel images (FAT1) were first captured with either identical
exposure time between wild type and mutants (D1,4 and D2,5, 421 ms), or with longer exposure time (D3,6, 2222 ms). This indicates that the epitope
detected by the anti-FAT1-ICD antibody (from ref [35]) is present in reduced but detectable amounts in Fat1LacZ/LacZ muscles. This observation was
made when Fat1LacZ/LacZ mice (n = 2 at P0; and n=3 at adult stages) displayed severe muscle defects at the stage of dissection, indicating that levels
of FAT1 protein inversely correlate with phenotype severity. Scale bars: (B–D) 4 mm, (C) 6 mm.
doi:10.1371/journal.pgen.1003550.g007
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severity. Consistently, in immunohistochemistry experiments on
muscle sections, residual FAT1 staining is also observed in
myofibres of Fat1DTM/DTM mutants and Fat1LacZ/LacZ mice, and
staining intensity in Fat1LacZ/LacZ mice that survived to adulthood
inversely correlated with phenotype severity at the level of
individual myofibers (Figure 7C,D and data not shown). Presence
of unchanged smaller FAT1 isoforms in muscles of Fat1DTM/DTM
mutants precludes using this mouse line to investigate their
function. However, it indicates that the phenotype of muscle
migration is not the consequence of their deletion, but results from
ablation (constitutive or driven by Pax3-cre) of the transmembrane
domain in full length FAT1 proteins that are abundant at
developmental stages (Figure 2B).
Fat1-deficient mice present characteristics of FSHD
Strikingly, the topography of selective alterations in muscle
shape that we observed during development in Fat1 mutant mice
closely resembles the map of muscles affected in early phases of
human FSHD. Muscle shape abnormalities such as those seen in
facial subcutaneous muscles, in trapezius, or in rhomboid muscles
are expected to result in lack of facial skin mobility and scapular
winging, two symptoms that are frequently the first clinical
manifestations of FSHD. The selective muscle weakness observed
in presymptomatic Fat1 mutants in muscles belonging to the
developmental map was also reminiscent of the early phase of
FSHD. Even at the scale of EM observations, defects in myofibre
structure, such as sarcolemma detachment (Figure 5D), included
aspects similar to those reported in FSHD biopsies [53]. Finally,
asymmetry of muscle symptoms is an important aspect of FSHD
symptoms. Asymmetries in muscle shape abnormalities were
observed not only in the robust phenotypes displayed by
Fat1DTM/DTM embryos, but also in the very subtle phenotypes
associated with by mild lowering of FAT1 expression in Fat1Fln/Fln
embryos (Figure 6, Figure S12A). In this context, it was interesting
to note that the human FAT1 gene is located at 4q35.2, 3.6 Mb
proximal to the D4Z4 array whose contraction is associated with
FSHD (Figure 8A). We therefore asked whether in addition to
muscle phenotypes, Fat1-deficient mice may also share similarities
with non muscular symptoms of FSHD. Besides muscular
abnormalities, the phenotypic spectrum of FSHD patients also
includes vision defects linked to vascular abnormalities [6,54–55].
As previously reported, constitutive FAT1 loss-of-function causes
abnormalities in eye development, with variable severity and
penetrance [36]. The Fat1LacZ/LacZ mice surviving as adults carried
milder phenotypes ranging from residual patterning defects
(aniridia, small eye, Figure 8B) to perfectly shaped eyes and
retina, in which analysis of vasculature with IB4 or PECAM
staining revealed numerous areas with intraretinal telangiectasia,
microvascular lesions, micro-aneurysms, and frequent retinal
detachments (Figure 8C). Additional non-muscular symptoms
associated with FSHD also include high frequency hearing loss,
although the cause of these deficits remains underexplored. Fat1-
deficiency was recently reported [56] to cause mild morphological
defects in the inner ear, such as reduced cochlear elongation, and
to exacerbate the appearance of ectopic sensory hair caused by loss
of FAT4, another FAT-like protocadherin, reflecting their
cooperation during in elongation and sensory hair cell patterning
in the cochlea [26,56–58]. Furthermore, owing to expression of
the MLC3f-2E transgene during inner ear development [59], we
observed shortening of the endolymphatic duct and endolymphat-
ic sac in Fat1DTM/DTM embryos at E12.5 (7 affected sides out of
12), this shortening being frequently asymmetric (Figure 8D, E).
These phenotypes are expected to influence audition. Thus, in
addition to the similarity of muscle abnormalities, adult Fat1
mutant mice also show non-muscular defects reminiscent of
clinical symptoms of FSHD. Nevertheless, the severity scale of
these phenotypes includes phenotypes more dramatic than those
seen in FSHD, and Fat1-deficiency also leads to phenotypes such
as the previously reported kidney abnormalities, that have no
equivalent in FSHD.
Deregulated FAT1 expression in human FSHD1 foetal
muscles
Considering the gene location and the provocative similarities
between Fat1-deficiency in mouse and FSHD, we therefore asked
whether alterations in Fat1 expression might be an essential step in
the molecular mechanism leading to FSHD pathology in human.
As in spite of the essential role of Fat1 in kidney development,
FSHD is not known to be associated with kidney abnormalities, if
a mechanism linking FSHD to Fat1 exists, it is expected to involve
partial functional alterations only, such as tissue-specific deregu-
lation of FAT1 during development. We thus first asked whether in
addition to the previously reported gene expression changes [9–
11,60], any deregulation of FAT1 expression levels could be
detected in the classical context of FSHD1, in which the pathology
is due to the presence of a contracted D4Z4 array on a permissive/
pathogenic DUX4-activating context (4qA haplotype) [17]. This
possibility was reinforced by the finding that FAT1 appears to be
downregulated by DUX4-fl, but not by DUX4-short in human
myoblasts [18]. This result was further validated by qPCR, after
lentiviral infection of human myoblasts with DUX4-fl as
compared with GFP control (Figure S15D), indicating that
DUX4 overexpression is capable of lowering FAT1 expression in
cultured muscle cells. As our results in mice point to the crucial
Figure 8. Selective changes in Fat1 mutant mice recapitulate the clinical picture of FSHD. (A) Schematic representation of the human
4q35.2 region, including 5 Mb upstream of the FSHD-associated D4Z4 repeat array. (B–C) Retinal defects and exudative vasculopathy in adult
Fat1LacZ/LacZ retinas. Fat1LacZ/LacZ eyes have an opaque appearance, in contrast to wild type eyes (B; yellow arrow). Removal of the cornea reveals
absence of opening of the pigmented retina (aniridia), which therefore covers the lens and prevents light from entering the eye. (C) Retinal
vasculature visualized using isolectinB4 (GS-IB4) staining of flat-mounted adult retinas from wild type and Fat1LacZ/LacZ mice. The retina of Fat1LacZ/LacZ
mice displayed zones in which the normal net of secondary and tertiary vessels was replaced by disorganized vasculature, revealing numerous intra-
retinal microvascular abnormalities, including IB4-binding microaneurysms (orange arrows). Insert: Example of severe retinal detachment (red arrows)
observed in Fat1LacZ/LacZ eyes, visible even through the lens prior to its removal during dissection. (D) The shape of the inner ear was visualized at
E12.5 in WT and Fat1DTM/DTM embryos owing to the MLC3F-2E transgene, which is expressed in the developing inner ear in addition to differentiating
muscles. Micrographs show an area of the face around the ear. This area shows: left: the masserter muscles (unaffected), bottom: a stream of muscle
cells migrating subcutaneously from the second brachial arch (future subcutaneous muscles of the face, which migration path is visibly affected); and
top right: the inner ear structure with the endolymphatic duct (ed), a long tube oriented dorsally, finishing with an enlarged area called the
endolymphatic sac (es). Both the ed and es are reduced in half Fat1DTM/DTM inner ears examined (frequently asymmetric). (E) Quantification of the
inner ear shape defect was performed by measuring the area occupied by the endolymphatic duct (ed) and endolymphatic sac (es), as illustrated with
the red dotted lines in (D). Each value for a given genotype were plotted on a vertical line, to illustrate the scale of variability of mutant phenotypes.
Scale bars: (B,C3) 0,5 mm; (C1–2) 200 mm; (C4–5) 80 mm, (C6) 30 mm.
doi:10.1371/journal.pgen.1003550.g008
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role of FAT1 deregulation during development, we aimed to
analyse FAT1 expression in rare cases of biopsies from foetuses
with a prenatal diagnosis of FSHD1, in spite of the fact that stages
of myoblast migration were not accessible to experimentation in
this context. Nevertheless, the observation that FAT1 protein is a
component of differentiated muscle fibres, enriched in the t-tubule
system, is consistent with additional later functions of FAT1
necessary for muscle integrity.
Possible alterations of FAT1 expression were therefore assessed
in muscle biopsies of human FSHD1 cases at foetal stages through
a series of independent approaches. Human FAT1 protein was
detected by immunohistochemistry in human muscle biopsies from
control foetuses of various stages with antibodies against FAT1 C-
terminal cytoplasmic tail, with a striped pattern similar to that seen
in mice (Figure 9A, Figure S15). We thus first studied FAT1
expression levels in tissues from an FSHD1 human foetus carrying
a pathogenic 4qA allele harbouring 1.5 D4Z4 copies, expected
from previous family history to lead to severe infantile FSHD
(Figure S14). Immunocytochemistry with anti-FAT1 antibodies on
sections from the quadriceps muscle revealed an overall decrease
in FAT1 protein levels compared to quadriceps biospies from
control foetuses (Figure 9A), with an irregularly stripped pattern of
FAT1 in myofibres that otherwise show a normal distribution of
other muscle proteins, such as DHPR. To assess this FAT1
lowering quantitatively, mRNA expression levels were then
followed by qRT-PCR in muscle biopsies from 4 FSHD human
foetuses carrying pathogenic 4qA alleles harbouring 1.5, 4.3, and 7
D4Z4 copies (referred to as F1, to F4, respectively; Figure S14A).
In F1 foetus, FAT1 levels were reduced 5-fold in the deltoid (a
muscle belonging to the FSHD map) and 3-fold in the quadriceps
muscles (a muscle traditionally affected only at late stages in the
human disease; Figure 9B). This was also confirmed by Western
Blot with anti-FAT1-ICD antibodies (Figure S15A). Additional
regulatory changes were detected (Figure S15B), such as an
increased level of MURF1 or dysferlin RNAs, while RNA of other
muscle components, such as DHPR or c-Sarcoglycan, were
unchanged, ruling out secondary effects of loss of muscle integrity
at this stage or quality of the biopsy. In contrast, no significant
difference in FAT1 mRNA levels could be observed in brain when
comparing FSHD and control samples from the same foetuses
(Figure 9B). Reduction of FAT1 mRNA levels, albeit to a lesser
extent (25% reduction; Figure 9B), and aberrant protein
localisation (Figure S15C) were observed in the quadriceps of a
second FSHD foetus harbouring 4.3 D4Z4 repeats (F2), from an
independent family with previous FSHD history (Figure S14).
Finally, no significant quantitative changes were observed in
Figure 9. FAT1 protein and RNA levels are mis-regulated in human foetal FSHD tissues. (A) Immunolocalization of FAT1 (Rb-1465 anti
FAT1-ICD, green) and DHPR (Cacna1s, magenta) in longitudinal sections from human quadriceps biopsies from a control (top) or and FSHD (F1,
bottom) foetus with 1.5 D4Z4 repeats. (B) qPCR analysis of FAT1 mRNA levels in quadriceps (3 left graphs) and deltoid muscles (middle graph) and in
brain (right graph), comparing respectively with age-matched control foetuses (blue bars), a 26 weeks old FSHD1 foetus (F1) harbouring 1.5 D4Z4
repeats in the 4q35 region (dark red bars), a 16 weeks old FSHD1 foetus harbouring 4.3 D4Z4 repeats at 4q35 region (F2), and twin FSHD1 foetuses
aged 28 weeks, with 7 D4Z4 repeats. (C) Analysis of the regulatory status of the promoter region by Chromatin immunoprecipitation. The respective
level of the following histone marks: H3K27me3 (silenced chromatin; C-left), and H3K4m3 (promoter active; C-right), in muscle extracts from four
age matched controls (ct1 to 4) or four FSHD1 foetuses (F1 to F4) are shown. Relative quantities were normalized with the level of histone marks at
the promoter of the GUSB gene as internal control, and expressed as % of control 1 (ct1). Scale bars: (A) 50 mm.
doi:10.1371/journal.pgen.1003550.g009
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Figure 10. Identification of contraction-independent FSHD patients carrying deletions of an intronic FAT1 enhancer. (A) View of the
Human genomic FAT1 locus focusing on an area including FAT1 exons 17-18-19. The lower image is a USCC browser based screen-copy image
showing a track displaying ENCODE enhancer and promoter associated histone mark (H3K4me1) on 8 cell lines. (B) Positions of copy number variants
identified in 5 FSHD patients by CGH and positioned on the genome by CGHweb analysis. Patients are identified with a specific number, and their
characteristics are available in the Table S1. The deletion span varies from deletions restricted to intron 17 to deletions spanning over intron 17, exon
17 and intron 16, including a ENCODE-putative enhancer visible through genomic browsers. (C) Copy number validation of the deletion by qPCR. The
three graphs show the relative amounts of PCR fragments obtained using primers couples 1–2 (exon 17), 2–3 (enhancer intron 16) and 4–5 (exon 16)),
in a group of 40 healthy controls (blue area), a group of 10 FSHD1 patients (red area), and a group of 19 contraction-independent patients (c.i.FSHD).
All data were normalized using an unrelated genomic fragment (Adora) as internal control, and one of the control DNAs (number 21) was used as the
reference DNA (where all values are set to 1). A cut-off of 0.75 has been set. Individuals in which the relative value is lower than the cut-off are
considered as having lowered copy numbers (indicated as loss). Information on each patient (regarding clinical and genetic diagnostic) are available
in the Table S1. (D) The distribution of CNVs corresponding to loss CNV (seen as red) is shown in controls and in FSHD groups (all together, or FSHD1
and c.i.FSHD separately) for each of the three spots considered individually (top three graphs) or considered together (bottom plot, where loss
represents the number of cases having a loss for at least one of the three spots). The cases where a significant link (as measured by X2 or Fischer tests)
are indicated with one or two stars (* for p,0.05; ** for p,0.001; p-values indicated in the result section). (E) Analysis by Chromatin
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muscle biopsies of twin FSHD foetuses with 7 D4Z4 repeats
(Figure 9B), although accumulation of FAT1 protein could be
observed in some myofibre nuclei (data not shown), a localization
never observed in age matched control biopsies, but reminiscent of
adult mouse muscles. In contrast to foetal stages, analysis of FAT1
mRNA levels in a series of adult FSHD1 biopsies or FSHD-
derived myoblasts did not reveal any significant change compared
to control biopsies or myoblasts (data not shown), a result
consistent with published data [10,60], or with data available on
GEO NCBI. Overall, these results indicate that 1) a reduction of
FAT1 levels in differentiated muscles can be observed is some
FSHD1 cases but is not common to all FSHD1 cases at the stages
examined; 2) the observed changes in FAT1 expression levels in
FSHD1 occur only during development.
We next asked whether the changes we observed were
accompanied with alterations in chromatin state around regula-
tory sequences of the FAT1 locus. We thus performed chromatin
immunoprecipitations (ChIP) on muscle biopsies derived from
these same FSHD1 and control foetuses (Figure 9C), looking for
potential changes in the levels of two widely studied chromatin
marks: H3K4me3 (trimethylation of histone H3 on lysine 4), a
mark of active promoters, and H3K27me3 (trimethylation of
histone H3 on lysine 27), which marks transcriptionally silent
chromatin [61–62]. Consistent with RT-PCR data, we observed a
significant decrease in the level of H3K4me3 decorating the FAT1
promoter region in the two FSHDs foetuses with less than 5
repeats, but not in the foetuses with 7 repeats, as compared to 4
control muscle biopsies of similar age range (Figure 9C right).
However, all 4 FSHD1 foetuses nevertheless showed a significant
increase in H3K27me3 levels (Figure 9C left). These data are
consistent with a switch in chromatin conformation towards the
silenced state in the same FSHD1 samples in which RNA levels
were reduced, a switch that has the potential to account for a large
part of the observed decrease in FAT1 levels.
CGH-based identification of contraction-independent
FSHD cases carrying deletions of an intronic regulatory
element of FAT1
FAT1 deregulation is not the only gene expression change
reported to be associated with the D4Z4 contraction causing
FSHD1. As we also wished to determine to what extent the
changes we found were relevant to the specific clinical phenotype,
rather than a silent consequence of the D4Z4 contraction, we
therefore extended our investigation to contraction-independent
FSHD cases. Such patients have typical FSHD symptoms, but are
not genetically associated to a pathogenic contraction of the D4Z4
array on chromosome 4. A large fraction of these contraction-
independent FSHD cases is now known as FSHD2, in which
hypomethylated D4Z4 repeats are combined with with a normal
sized D4Z4 array on chromosome 4 permissive for DUX4
expression [22,63–64]. Besides, other rare cases of contraction-
independent FSHD cases remains unexplained, and represent
interesting candidates to test whether alterations of the FAT1 locus
might be directly associated with FSHD. To identify such
alterations of the FAT1 locus, we performed an array-based
comparative genomic hybridization screen (CHG [65]), a method
used to uncover copy number variants. The custom-designed
CGH array we employed covered the whole FAT1 genomic
region, including non-coding sequences. In our CGH survey of 29
FSHD cases, including 10 FSHD1 cases and 19 contraction-
independent cases (5 of which at least not showing D4Z4
hypomethylation, see Table S1 for clinical and genetic character-
ization of patients), we detected 5 cases exhibiting loss of portions
of the intron 17 (between exons 17 and 18), or intron 16 of the
FAT1 gene (Figure 10A,B, Figure S16). Besides the overlap with
exon 17, we noticed that these deletions mapped near or within a
hot spot of H3K4me1 methylation, a hallmark of cis-regulatory
enhancers [61], spanning across intron 16 and part of intron 17
(Figure 10A, and Encode high throughput data, available on the
UCSC browser [66]). According to the ENCODE ChIP seq data
set [67], this element appears labeled as having strong enhancer
activity in a human skeletal muscle myoblast line (HSMM) but not
in 8 other non-muscle cell lines (Figure S16B). Examining the
chromatin status at this locus by ChIP experiments, we
consistently found that in control foetal muscle biopsies, intron
16 but also intron 17 were decorated by high levels of the
enhancer signature H3K4me1 and negligible amounts of
H3K4me3 (promoter signature) (Figure 10D, blue lanes, and data
not shown), providing further in vivo support to the possibility that
this sequence might indeed act as regulatory element in vivo.
To determine whether loss of functional portions of the putative
enhancer were associated with FSHD, we analyzed copy number
variants (CNVs) in a set of 40 healthy controls, 19 contraction-
independent FSHD cases, and 10 FSHD1 cases. As the sensitivity
of the CGH method might not allow detecting all cases with
accurate precision, we applied a more precise qPCR method, and
evaluated relative copy numbers by comparing 3 positions within
and around the putative enhancer to a control spot on another
chromosome (Figure 10A, C; 3 additional positions shown in
Figure S16). Having set the threshold for considering a genome as
carrying reduced copy numbers (loss) to 75% of the value in a
healthy control used as reference genome, we found some healthy
controls that exhibited reduced copy numbers of genomic regions
at the core of the H3K4me1 hotspot in intron 16 (5% of controls)
or in either surrounding exons (10% of control cases in both cases).
This finding is consistent with a study, available through public
datablases, that identified cases with loss of similar genomic
segments at this locus in a group of 90 healthy individuals [68].
Thus, such deletions/copy number reductions are not sufficient on
their own to cause FSHD symptoms, when occurring on only one
allele of FAT1. However, in all three positions, the proportion of
FSHD cases (all cases included) who exhibited loss was signifi-
cantly higher than the proportion of healthy controls carrying
reduced copy numbers at the same spot (Figure 10C,D; X2 test, p
values,0.016; ,0.00075; and ,0.00041, for exon 17; enhancer;
and exon 16, respectively). Cases with a deletion spanning the
whole region were also significantly more frequent in the FSHD
group than among controls. When considering only contraction-
independent FSHD cases, as much as 47% carried the CNV
including the putative enhancer, as compared to 5% of controls,
and up to 68% carried a CNV encompassing at least one of the
three considered positions, as opposed to 20% of the controls
immunoprecipitation of the relative enrichment of the chromatin marks H3K27me3 (silenced chromatin), H3K4m3 (promoter active), and H3K4me1
(enhancer active), at the level of the intronic enhancer located between exons 17 and 18 of FAT1, in muscle extracts from two age matched controls
and FSHD1 foetus F1. (F) Schematic summary of the finding, showing a conformation switch of the chromatin to repressed state in FSHD1 foetal
muscle (in cases with severe expected outcome with ,5 D4Z4 repeats), at the level of both the promoter and the intron 17/18 enhancer of FAT1
exons (middle). (bottom) Deletions of part of all the enhancer at introns 16/17 are predicted to interfere with tissue-specific regulation of FAT1
expression, and. represent (when carried on one allele) a polymorphism that segregates with FSHD (FSHD1 and c.i.FSHD).
doi:10.1371/journal.pgen.1003550.g010
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(Figure 10C,D, Fischer test, p,0.0004 and p,0.0001 for
enhancer and exon 16, respectively). Conversely, when consider-
ing the distribution of cases with increased copy numbers (gain,
above a threshold of 1.256 over the average control value) we
found that there were significantly less FSHD cases with gain-
CNVs than among the control group (X2 test, p,0.017 and
p,0.014 when considering all FSHD cases or contraction-
independenty cases only, respectively). Finally, we also analyzed
the methylation status at D4Z4 repeats on chromosome 4 on a
subset of our group of contraction-independent FSHD patients (5
out of 19), and found no indication of hypomethylation (at the
CpoI site, Table S1) on the proximal D4Z4 unit [64]. This does
not exclude that others patients in our c.i-FSHD group would be
diagnosed as FSHD2, but indicates that FSHD can occur in non-
contracted patients independently of the hypomethylation, known
FSHD2 hallmark [22,64]. Together, these results indicate that
partial or complete deletions of FAT1 intron 16/17 putative
enhancer represent a polymorphism not sufficient to cause FSHD
by itself when present on one allele only of chromosome 4, but
which segregates with FSHD. Therefore, this CNV can be
combined with pathogenic or sub-pathogenic contexts, and may
act as a novel disease modifier in FSHD.
Discussion
FAT-like cadherins play various roles in tissue morphogenesis,
by modulating cell polarity, adhesion and tissue growth. Here we
show that during development, FAT1 controls the shape of subsets
of muscles in the facial and scapulohumeral regions, and does so
by modulating the polarity of collective myoblast migration, a
function in accordance with the emerging link between planar cell
polarity and collective directional migration events [29–30,69].
These muscle shape abnormalities are predictive of early onset
muscle wasting, as observed in Fat1-deficient mice that bypassed
neonatal lethality. Using Pax3-cre for conditional ablation of Fat1
functions in premigratory myoblasts, we show that a cell
autonomous requirement for Fat1 function in the migrating
myoblasts accounts for a significant component of this role in
shaping muscles. Taken together, the location of the human FAT1
gene next to the critical FSHD locus at 4q35, the similarity
between the Fat1-dependent muscles and those affected in FSHD,
and the appearance in Fat1 mutants of non-muscle features of
FSHD, suggest a possible role of FAT1 in the pathophysiology of
this disease. In our human studies, we found two ways by which
altered FAT1 regulation underlies a link with FSHD: 1- we
observed muscle-specific lowering in foetal FSHD1 biopsies; 2- we
identified a polymorphism deleting a putative cis-regulatory
enhancer in the FAT1 locus, which significantly segregated with
FSHD. Together, these results strongly support the idea that
tissue-specific de-regulation of FAT1 expression/function might
play a critical role in FSHD pathophysiology.
Fat1 is required in migrating myoblasts to shape
selective muscles in the face and shoulder
The altered myoblast migration polarity caused by loss of Fat1
functions leads to selective developmental dysgenesis of scapulo-
humeral and subsets of subcutaneous muscles of the face.
Understanding how Fat1 controls muscle shape required first
determining which part of its expression domain accounts for this
function. In addition to the muscles, Fat1 is expressed in several of
the cell types that interact with migrating muscle cells. The highest
expression was seen in non-muscle cells, such as the subcutaneous
layer towards which CM myoblasts migrate (Figure 1). This
muscle-skin interface is analogous to the bone-muscle interfaces
(tendons, joints) of skeletal muscles, where Fat1 also accumulates at
later stages (Figure 7A). Here, however, we show that ablating the
floxed transmembrane domain of FAT1 with a Pax3-cre knock-in
line leads to efficient excision in premigratory muscles of the limb
but not the face, and reproduces at least partially the migration
phenotype observed in constitutive Fat1 knockouts in the
scapulohumeral region. Pax3-cre excision does not occur in motor
neurons, hence ablation in this cell type does not contribute to the
phenotype observed in Fat1Fln/Fln;Pax3 cre/+ embryos. No signifi-
cant muscle shape defects were caused by Pax3-cre -mediated Fat1
ablation in subcutaneous muscles of the face. This is not
surprising, as muscles in the face do not derive from Pax3-
expressing precursors but were previously shown to derive from a
subset of islet1-expressing pharyngeal mesoderm cells [46,70]. In
addition to trunk migrating myoblasts, Pax3-cre-mediated excision
occurs in dorsal neural tube and neural crest. Although Fat1
expression is detected in Schwann cells (neural crest-derived) along
the nerves at P0, we did not detect such an expression at the stage
of muscle migration (E12.5, see Figure S11C), making it unlikely to
for Fat1 to control migration polarity by acting in neural crest
derivatives. Furthermore, as Pax3-cre-derived neural crest amply
colonizes the developing face, the lack of enhanced muscle
phenotype in the face of Fat1Fln/Fln;Pax3 cre/+ embryos disqualifies
the neural crest component of Fat1 expression from playing a
major contribution in muscle shaping, and strongly suggests that
Fat1 is required cell-autonomously in migrating myoblasts to
control the polarity of their migration. As however, the muscle
phenotype of Fat1Fln/Fln;Pax3 cre/+ embryos is significantly weaker
than the phenotype of constitutive mutants, it leaves the possibility
that other component of Fat1 expression domain may also
contribute to its function in muscle patterning.
The rationale for why such a selective group of muscles is
affected by Fat1 loss of function is still unclear. This group of
muscle includes subsets of migratory muscles of the face and
shoulder area. In the face, defects are restricted to branchiomeric
muscles derived from the second brachial arch (subcutaneous
muscles of the skin, Figure 3), while first branchial arch derived
muscles (masseters and temporalis), as well as extraocular muscles,
are unaffected (Figure 5 and data not shown) [70–72]. The
scapulohumeral region can be divided in two components: 1) the
CM, as well as humeral muscles (triceps, deltoid, or muscles which
pattern is affected by the supernumerary muscle) derive from
somitic Pax3-driven hypaxial migratory precursors (Figure S10); 2)
In contrast, some of the shoulder muscles such as the acromio-
trapezius and spinotrapezius, or the rhomboids, belong to the
cucullaris group and were previously shown to derive from non-
somitic, occipital lateral plate mesoderm [46,72–73]. Such
specificity is in apparent contrast with the broader expression
domain of Fat1 in muscles as observed at E12.5 and later (Figure 1,
7, and S1), although clear differences in expression levels between
muscles can be distinguished (Figure 7A). Given that distinct
regulatory programs govern the development of these muscle
groups [2,74], the selective impact of Fat1 on muscle shapes could
be determined by its interaction with some of the selective
myogenic regulators.
Does altered muscle shape predispose to muscle wasting?
Advanced symptomatic stages in Fat1-deficient mice are likely
systemic consequences of such non-muscle phenotypes. Neverthe-
less, the muscle wasting and dystrophic features measured at
presymptomatic stages were detectable selectively in those muscles
that exhibited myofiber orientation defects, even in cases with no
other detectable phenotypes. Despite the important variability in
postnatal phenotype strengths observed with the Fat1LacZ allele,
Deregulated FAT1 Expression as a Model of FSHD
PLOS Genetics | www.plosgenetics.org 17 June 2013 | Volume 9 | Issue 6 | e1003550
myofibre orientation defects and dystrophic features in the CM
and shoulder muscles (Rhomboids, Trapeze) were observed in all
mutant cases examined, not only of embryos, but also at adult
stages, even in cases of Fat1LacZ/LacZ mice surviving to old ages with
no other detectable phenotype. This specificity argues against the
idea that restricted topography of muscle defects would be a
consequence of renal problems or of other non-muscular defects.
Furthermore, the observed match between the topography of the
developmental phenotype and the specific map of muscles that
undergo wasting at presymptomatic stages in adult Fat1LacZ/LacZ
mice supports the idea that the selective muscle degeneration
might occur as a consequence of the altered muscle shape. Future
experiments will be necessary to determine whether the limited
defects observed in Pax3-cre/Fat1 embryos are sufficient to
predispose muscles to early onset degeneration, and whether
additional triggers might be required for degeneration to occur in
adult life. Among phenotypes observed in adult Fat1-deficient
muscles, it will also be interesting to distinguish secondary
consequence of the altered muscle shapes, from phenotypes
reflecting additional, independent functions of Fat1, whether
exerted in muscles too or in other cell types.
Tissue-specific de-regulation of FAT1 as a potential
mechanism in FSHD pathogenesis
The spatial distribution of muscles mis-shaped as a result of Fat1
loss of function as seen at E14.5/E15.5 (Figure 3) appears to
overlap very closely with, and thus to predict, the map of muscles
affected at early stages in FSHD. Furthermore, the observation of
non-muscle phenotypes such as defects in retinal vascularisation or
inner ear patterning also bears some similarities with symptoms
observed in FSHD patients. Despite this strong concordance
between the phenotype of Fat1-deficient mice and FSHD
symptoms, the selectivity of the shared phenotypes raises a
paradox. Fat1 expression during development is not restricted to
FSHD-relevant tissues, and constitutive deletion of Fat1 leads to
pronounced renal defects and neonatal lethality. Even the Fat1
hypomorphic phenotypes presented above cannot be considered
as an exact phenocopy of FSHD. Overall this mouse model is also
more severe than FSHD, and 50% of the mice die within 3
months, likely of milder versions of the kidney phenotype (such as
polycystic kidney). In contrast, FSHD is not known as a lethal
disease, and has no reported association with kidney problems.
Absence of renal dysfunction in FSHD is a strong indication that
FSHD cannot simply be considered a ‘‘FAT1 knockout’’. Thus,
cases of patients with severe FAT1 loss of functions and kidney
failure might be fatal before onset of muscle dystrophy and might
thus fail to be classified as FSHD. In support of this hypothesis, a
rare case of a 5-year-old girl carrying a duplication of the D4Z4
array and showing vascular retinopathy and sensorineural deafness
was also reported to have focal glomerulosclerosis of the kidney
[75]. Instead, lack of association between FSHD and renal
dysfunction indicates that any FSHD mechanism involving FAT1
alterations must necessarily preserve FAT1 expression/function in
kidney (at least). Our results with mice suggest that such selective
alterations of FAT1 function/expression may matter during
development, in muscle precursors, at a stage when their
migration occurs, for which FSHD human material was not
available so far - and can ethically not be sought. FAT1 levels may
not be changed to an equal extent in all tissues and times,
consistent with our observation that FAT1 levels were reduced in
disease-relevant muscles but not in brain, and at foetal but not
adult stages. Thus, an engineered mouse model in which Fat1
functions are specifically ablated in muscles and preserved in the
renal system, even though lacking effects of other DUX4 target
genes, may represent a more suitable tool to study consequences of
the muscle abnormalities in adult, and a better model reflecting
the tissue-specific FAT1 depletion that we propose might be
occurring in FSHD.
Loss of a putative FAT1 enhancer as a novel disease
modifier in FSHD
The finding that human cases of contraction-independent
FSHD, with such a characteristic and restricted set of clinical
symptoms, segregate with the deletion of a putative regulatory
genomic element in the FAT1 locus instead of the traditional D4Z4
contraction, strongly supports the idea that altered FAT1
regulation plays a key role in the pathology. The putative cis-
regulatory enhancer reported in this study, which deletion
segregates with FSHD in contraction-independent cases is likely
to carry tissue-specificity information driving FAT1 expression in
FSHD-relevant cell types, and future experiments are required to
demonstrate such activity. The finding that healthy controls can
exhibit heterozygous loss of this fragment of the FAT1 locus,
containing two exons and an enhancer, is consistent with the
observation that heterozygous loss of Fat1 functions in mice does
not have major consequence of life span, health, and muscle
integrity. However, we did observe a significant degree of
haploinsufficiency in Fat1DTM/+ embryos, evidenced by the
presence of subtle muscle shape defects (Figure 6B,C, see indicated
p values), the most frequent position being between the
acromyotrapezius and spinotrapezius muscles (as in Figure 3B).
Such phenotypes were also consistently detected in Fat1Fln/Fln
embryos (Figure 6 and Figure S10D), in which expression levels
were similar to those measured in Fat1DTM/+ embryos (Figure
S10B, C), suggesting that muscles in the shoulder area are highly
sensitive to Fat1 dosage. While copy number variants outside of the
putative enhancer might occur without causing any regulation
change, we reasoned that the further such deletions would extend
into the ENCODE predicted enhancer, the more functional
transcription factor binding sites they may remove, hence
increasingly interfering with FAT1 regulation on the deleted allele,
thereby sensitizing the locus to additional contexts that may
additionally impact on FAT1 expression.
Interestingly, two of the FSHD1 cases presented here were
monozygotic twins, both carrying a contracted 4q35 allele with 3
D4Z4 units, one of the twins being asymptomatic while the other
twin had been diagnosed with a classical FSHD. We found that
the twin with FSHD symptoms displayed reduced copy numbers
throughout the length of the studied area, encompassing both
exons 16 and 17 and the intron 16 putative enhancer, while the
asymptomatic twin exhibited reduced copy numbers only at the
distal-most region towards exon 16, this difference possibly
representing a de novo somatic mutation (Figure 10 and Table
S1). Although this correlation does not constitute a demonstration
of causality, it provides support to the hypothesis that this lowered
copy numbers (heterozygous) of FAT1 exons 17/16 and of
portions of the putative FAT1 enhancer portions have the
potential to worsen FSHD symptoms when combined to a
pathogenic context. However, obtaining a formal demonstration
of this hypothesis will require studying phenotypes/genotype
correlations on a large cohort of patients, and knowing in each
case if the FSHD-causing genetic context is FSHD1, FSHD2, or
other un-identified contraction-independent contexts. Overall,
deregulation of the FAT1 gene is associated with FSHD, either
as a consequence of DUX4 overexpression, and/or epigenetically
encoded in FSHD1 and FSHD2, or through the deletion of a
putative enhancer that segregates with contraction-independent
FSHD patients.
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An additional function for FAT1 in muscle differentiation
and/or physiology?
Among possible products of the Fat1-gene, our results in mice
indicate that the control of migration polarity and muscle shape
requires a Fat1 RNA containing a transmembrane domain
encoded by the floxed exons and deleted in the Fat1DTM allele. In
contrast, other functions can be executed by incomplete Fat1
isoforms. Residual RNAs containing 39 Fat1 exons can rescue (to
an extent correlating with RNA levels) kidney defects and their
consequences, but not muscle dysgenesis. Interestingly, however,
both mouse models retain the capacity to produce FAT1 protein
isoforms containing an intracellular domain, albeit at reduced
levels quantified by qPCRs (Figure S10B,C), ruling out a major
contribution of these isoforms to the muscle shape phenotypes
observed in both mouse models. In muscle fibres, FAT1 is a
novel component of t-tubules. Does Fat1 expression in differen-
tiating and mature muscle reflect additional functions in muscle
biology? The presence of FAT1 protein in close association with
the contractile apparatus, as soon as differentiation starts, may
reflect a role in sarcomere assembly. These FAT1-enriched
stripes are maintained in mature muscle fibres, tightly juxtaposed
with the t-tubule system (Figure 7B). This may indicate a further
involvement in excitation-contraction coupling, an essential
process required throughout adult life for muscle function and
maintenance. However, this striped pattern is established as
early as the contractile apparatus assembles (Figure 7C), before
the alignment and docking of T-tubules to the contractile
apparatus takes place, the latter phenomenon occuring postna-
tally in mice [76]. This indicates that in muscle, FAT1 isoforms
are not inserted in the t-tubule compartment itself, but may be
located at an interface juxtaposing t-tubules and the contractile
units, possibly reflecting a new function for Fat1 for example
during assembly of the t-tubule network. As myoblast migration
precedes differentiation and sarcomere assembly, the accumula-
tion of these FAT1 protein isoforms in the contractile apparatus
occurs too late to be accountable of the function in migration
polarity.
FAT-like proteins were previously reported to be subject to
various cleavage events by Furin convertase or by a- or c-
secretases [50–52]. Furthermore, alternative splicing events in
the cytoplasmic exons were reported to influence subcellular
targeting of FAT1 proteins [48]. Our work in mice unexpectedly
indicated that in addition to producing a large transmembrane
protein and its cleavage products, the Fat1 gene also produces
small molecular weight protein products which appear not to
contain a transmembrane domain, and synthesis of which is
largely preserved in both Fat1-deficient mouse models, although
at reduced levels. Bioinformatic scans and existing ESTs
reported on all genomic browsers are indeed consistent with
the possibility that short isoforms may result from transcript
initiation at alternative downstream promoters, and may code
for protein products devoid of leader peptide and transmem-
brane domain and potentially produced in the cytosol (lacking a
leader sequence). Thus, understanding the roles played by the
isoforms of FAT1 produced in muscles will require first
characterizing the exact exon and domain composition of the
Fat1 RNA and protein isoforms produced in muscle (wild type
and Fat1DTM/DTM), and second designing novel strategies to
ablate them independently of the transmembrane domain
containing isoforms.
Interestingly, residual expression of such muscle-specific
isoforms is genetic background dependent and its levels in
Fat1LacZ/LacZ mice inversely correlated with phenotype severity.
Furthermore, reduced expression levels and abnormal sub-cellular
localization were observed in muscle of human foetal cases with
expected severe and early onset FSHD1 (as predicted by the
degree of D4Z4 contraction and family history), while no
significant changes in RNA levels were detected in adult FSHD1
muscles compared to controls. These observations are consistent
with the idea that deregulated FAT1 expression in differentiated
muscle may be predictive of early (infantile) onset and severe
dystrophy. These data suggest that the causes of the early phase,
common to all FSHD patients and restricted to muscles of the face
and shoulder, might be uncoupled from the causes of later phases
of the disease - which spreads to other muscles, a condition that
occurs in a subset of FSHD patients with childhood onset, the
latter ending up wheel-chair bound [6].
Link with the known mechanisms in FSHD1
Recent studies have brought to light several possible molecular
pathways by which the D4Z4 contraction on a 4qA allele may
exert its pathological effect in FSHD1. Among those, stabilization
of DUX4-fl mRNAs by polyA-creating polymorphisms was shown
to enable expression of a toxic form of DUX4, the latter causing
muscle dystrophy through altered regulation of numerous target
genes, including Pitx1, p53, and other germline-specific genes or
myogenic regulators [17–21,23–24]. Another mechanism involves
production by the contracted region of DBE-T, a chromatin-
associated long-non-coding RNA that causes de-repression of
several 4q35 genes [77], including FRG1, whose overexpression
was previously proposed to contribute to causing muscle
degeneration too [11–12]. Other mechanisms also influencing
4q35 gene expression include a telomeric position effect, according
to which propagation across 4q35 of changes in methylation or
chromatin conformation might be due to the loss of the CTCF
barrier function of the D4Z4 array [8,13,78]. The relative
contribution of DUX4-mediated gene regulation and of mecha-
nisms leading to altered 4q35 gene expression is controversial
[9,17] and may reflect an underestimated diversity in the clinical
expression of FSHD1 [79–80]. Understanding which of these
mechanisms, or what combination, contributes to modifying
tissue-specific distribution of FAT1 will require developing cellular
or animal models adequately reproducing FSHD mechanisms and
mimicking in vitro key steps of muscle shape development. This
will also allow defining whether there are differences in the
sensitivity to a contracted allele between developmental stages and
adult muscle, but also between FAT1 isoforms. DUX4 can repress
FAT1 expression in human myoblasts ([18] and Figure S15D).
Such regulatory influence could involve some DUX4 target genes
such as p53 [37–38], or myogenic transcription factors. Our data
suggest that irrespective of whether FAT1 is regulated by DUX4,
by DBE-T, or by anyone of their respective downstream or
upstream targets, this regulation must occur primarily during
development, in the cell type in which FAT1 is required to control
migration polarity. This model does not exclude the possibility that
the pathogenic 4q35 allele may further contribute to directly
triggering muscular dystrophy in adult muscle, through additional
mechanisms independent of FAT1 de-regulation.
Can deregulated FAT1 in FSHD lead to altered PCP/
Frizzled signaling?
A number of clinical features of FSHD, including non-muscular
symptoms such as hearing loss and retinal vasculopathy [81–82],
carry the signature of defects in the Wnt/PCP pathway [26], a
cascade of tissue polarity regulating genes, involving non-canonical
Wnt/Frizzled signalling (core PCP genes) and modulated by the
protocadherins FAT and Dachsous [25,27]. Sensory hair cell
polarity in the cochlea is the best mammalian PCP paradigm, and
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deafness has become a traditional hallmark of altered PCP
signalling [26,57–58]. Even through the anatomical nature of
auditory abnormalities in FSHD is not known, it will be relevant to
explore whether it carries further characteristics in common with
altered PCP. Furthermore, vascular abnormalities in the retina,
also known as Coats disease, are phenotypically similar to familial
exudative vitroretinopathy (FEVR), recently linked to mutations in
the Wnt receptor Frizzled4 (FZD4) and its ligand Norrin [83–85].
Moreover, the Wnt/PCP pathway is also known to play key roles
in muscle biology. PCP-activating Wnts, such as Wnt11 or Wnt7a
act as instructive signals for myofibre orientation during muscle
morphogenesis [86], for muscle satellite cell expansion through
symmetric division [87], and for neuromuscular synapse develop-
ment [88]. Thus, altered regulation of FAT1 may in turn de-
regulate the function or expression of its genetic partners, such as
other components of the planar cell polarity cascade but also of the
Hippo pathway. Mutations in other components of these genetic
cascades may also play a causal role in a subset of the FSHD
patients lacking the D4Z4 contraction. Overall, by linking FSHD
to FAT1, our work opens new avenues for the exploration and
treatment of this and other neuromuscular disorders.
Methods
Ethics statement
Animals were maintained and sacrificed in accordance with
institutional guidelines. Adult mice were either sacrificed for
experiments through anaesthesia, or euthanized by cervical
dislocation. Efforts were made to minimize the number of adult
Fat1-deficient mutant mice examined after more than 25% weight
loss.
Human DNAs were obtained from FSHD and control cases at
La Timone Hospital (Marseille, France). The protocol for their
collection was approved by the Universite´ de la Me´diterrane´e
(Marseille, France) Committee on Human Research and an
agreement of informed consent authorizing scientific experiments
was signed by each individual patients. Human Tissues samples
were obtained from abortus cases at La Timone Hospital
(Marseille, France) and at AP-HP (Assistance Publique-Hopitaux
de Paris, France). The protocol for their collection was approved
by the Universite´ de la Me´diterrane´e (Marseille, France) Com-
mittee on Human Research and an agreement authorizing
scientific experiments was signed by the parents. Termination of
pregnancy (performed at the stages corresponding to individual
cases) was decided after late prenatal diagnosis.
Mouse lines
Characterization and genotyping of the Fat1LacZ
allele. Fat-LacZ mice, previously generated using the genetrap
ES line KST249 (see detailed characterization below), were
obtained from Marc Tessier-Lavigne. Initial characterization of
the transgene insertion site on Fat1 transcript was performed by
59RACE PCR (as documented on the international genetrap
consortium databases (http://www.genetrap.org/cgi-bin/
annotation.py?cellline =KST249) indicated insertion downstream
of the first exon. Genome walking experiments (LAM-PCR,
GATC Biotech; plasmid rescue, restriction analysis by Southern
blot) consistently indicated that multiple copies of the transgene
were inserted in tandem, thus preventing so far identification of
genomic sequences flanking the transgene. Genotyping was
performed on genomic DNA using the following PCR to detect
the transgene (primer sets OF47: 59 GGA ACT TCT CAG ATC
TGC GGG CTGC 39; and OF48: 59-TCT CAT CTT GGG
TGA GGT GGG TCCC-39; or OF49: 59-GGA ACT TCT GGA
TCT GCG ATC TGCG-39 and OF57: 59 CCC CAA ACA CTG
CCA ACT ATG-39). To recognise heterozygotes (one mutant
allele) from homozygotes (two mutant alleles) at postnatal and
adult stages, we performed dot blot hybridization experiments
(using a beta-geo probe made with OF47-OF48 PCR product,
dig-labelled by random priming) and discriminated difference in
staining intensity, or qPCR analysis, using OF47 and OF48
primers for the transgene, and the following primers as reference
(met primers wt: FM20: 59 AAG CTT CTG GTT CTG ATG
CTC TGT CAG -39; Met-610: 59- AGG ATT GAT CAT TGG
TGC GGT C – 39). At embryonic stages, we also performed X-gal
staining on yolk sacs (or any dissected fragment of embryo), the
intensity of staining being a reliable indicator of the genotype until
E16.5.
To follow progression through adult phenotype, each mouse’s
weight was measured weekly, and the weight at a given stage is
compared to it maximal measured weight. Mice with less than
10% weight loss are considered presymptomatic (with respect to
systemic consequences of phenotypes such as kidney filtration
defects).
Transgenic mouse lines. Gdnf-lacZ mice were used with
permission of Genentech, and genotyped as previously described
[40]. Mlc3f-2E transgenic mice were kindly provided by Robert
Kelly, and genotyped as previously described [43]. Pax3-cre knock-
in (Pax3tm1(cre)Joe line [89]) mice were used with permission of
Jonathan Epstein and genotyped with the following generic CRE-
specific primers: MSP4: 59-ATC CGA AAA GAA AAC GTT
GA-39; MSP5 59-ATC CAG GTT ACG GAT ATAG T-39.
Rosa26-YFP mice (Gt(ROSA)26Sortm1(EYFP)Cos line, [90]) were
kindly provided by Teddy Fauquier and obtained from the
Jackson laboratory (mouse strain 006148), and were genotyped
following Jaxmice instructions.
Generation of Fat1 conditional and constitutive
mutants. Mice carrying a conditional Fat1DTM allele were
constructed in the research facility of iTL (ingenious Targeting
laboratories, genetargeting.com). Construction of mice with the
conditional Fat1DTM allele began by isolation of the 129 SvEv BAC
clone RP22: 41E14, containing the murine sequence of the Fat1
locus, including the exons 24 and 25, which we aimed to flox, exon
25 containing the transmembrane domain. An 11 kb region used
to construct the targeting vector was first subcloned from the BAC
using a homologous recombination-based technique. The region
was designed such that the short homology arm (SA) extends about
2.3 kb to the 59-end of the LoxP/FRT-flanked Neo cassette. The
long homology arm (LA) extends 6.22 kb to the 39-end of the
single Lox P site. The single Lox P site is inserted upstream of exon
24 in intron 23–24, and the LoxP/FRT-flanked Neo cassette is
inserted downstream of exon 25 in intron 25–26. The target
region is ,2.6 kb containing exons 24–25. The BAC was sub
cloned into a ,2.4 kb pSP72 (Promega) backbone vector
containing an ampicillin selection cassette for retransformation
of the construct prior to electroporation. A pGK-gb2 LoxP/FRT-
flanked Neomycin cassette was inserted into the gene as described
in Figure S4. The targeting construct can be linearized using NotI
prior to electroporation into ES cells. Ten micrograms of the
targeting vector was linearized by NotI, and transfected by
electroporation of iTL1 129/SvEv embryonic stem cells. After
selection with G418 antibiotic, surviving clones were expanded for
PCR analysis to identify recombinant ES clones. Screening
primers A1 and A2 were designed downstream of the short
homology arm (SA) outside the 39 region used to generate the
targeting construct. PCR reactions using A1 or A2 with the F3
primer (located within the Neo cassette) amplify 2.42 or 2.51 kb
fragments, respectively. The control PCR reaction was performed
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using the internal targeting vector primers AT1 and AT2, which
are located at the 39 and 59 ends, respectively, of the SA. This
amplifies a product 2.05 kb in size. Primers for PCR Screening :
A1: 59- AAG CTT CCT GCT GTC ACT AAG G -39; A2: 59-
ACG TGC ATG TTA ACT GGG TAC AC-39; AT1: 59- AGG
TTC TGA ACA GGG AAT GAA ACG – 39; AT2: 59- TCT
GTT GAG CAT ATG TGC AGA TC – 39; OUT1: 59- GGC
TGC TAC GTC TCA GGG C – 39; F3: 59- GCA TAA GCT
TGG ATC CGT TCT TCG GAC – 39. Individual clones from
positive pooled samples were screened using A1 and F3 primers.
Positive recombinant clones were identified by a 2.42 kb PCR
fragment. A PCR was performed on SA positive clones to detect
presence of the third LoxP site using the LOX1 and SDL2
primers. This reaction amplifies a wild type product 390 bp in
size, and a product from the targeted locus of 452 bp in size. 3
clones were reconfirmed for SA integration and third LoxP site
retention using the same methods as described above. All
reconfirmed clones were sequenced to verify SA integration and
retention of the third LoxP site. Secondary confirmation of
positive clones identified by PCR was performed by Southern
Blotting analysis. DNA was digested with NcoI, and electropho-
retically separated on a 0.8% agarose gel. After transfer to a nylon
membrane, the digested DNA was hybridized with a probe
targeted against the 39 external region. PB1/2 Probe Primers: PB1
59-TCA GCT CAC CCA GCT AAT GC – 39; PB2 59-TCA ACG
ACA GCG TTG ACA AGG – 39. Positive clones identified by
PCR were further confirmed by Southern Blotting analysis with an
internal probe. DNA was digested with NcoI, and electrophoret-
ically separated on a 0.8% agarose gel. After transfer to a nylon
membrane, the digested DNA was hybridized with a probe
targeted against the 39 internal region. Two clones were confirmed
as correctly targeted and used for injection in blastocysts. Targeted
iTL1 (129/SvEv) embryonic stem cells were microinjected into
C57BL/6 blastocysts. Resulting chimeras with a high percentage
agouti coat color were mated to wild-type C57BL/6 mice to
generate F1 heterozygous offspring. Tail DNA was analyzed as
described in Figure S4A from pups with agouti coat color.
Heterozygous F1 offspring carrying the targeted allele were further
reconfirmed using the PCR conditions used for ES screening (A1
and F3 primers). Germline transmission of the targeted allele was
obtained for one recombined ES clone.
Mice carrying the targeted locus (refered to as Fat1Fln allele, as it
contains the floxed exon and the neo cassette) were amplified, and
kept as either heterozygotes or homozygotes, as Fat1Fln/Fln males
and females are viable and largely fertile. Mice carrying the Fat1Fln
allele were crossed with mice carrying the ubiquitous cre (Deleter-
cre line, official name Tg(CMV-cre)1Cgn [91]) to produce
offspring with a recombined allele (Refered to as Fat1DTM). After
elimination of the Deleter-cre transgene, a line with the recombined
allele was maintained separately from the line carrying the original
Fat1Fln allele. Fat1DTM/+ (also carrying the MLC3F-2E transgene)
were bred to produce Fat1DTM/DTM embryos or mice. Genotyping
primers (numbered according to Figure S3): Primer 1 (OF165) : 59
- GTA GGG ACG TTC TGT GAG GTG AGC G – 39 ; primer
2 (OF166): 59 – CTG TGG AAA GGG CGC AGC AGA AAC G-
39; primer 3 (ON17) : 59 - AAC TCG CCC TCA GAC AGC
GAC TCC - 39; Primer 4 (ON16); 59 – GGG ATC CAG ATC
TAC CAC TTT AGC TG – 39; Primer 5 (Uni): 59 - AGC GCA
TCG CCT TCT ATC GCC TTC; Primer 6 (LAN1): 59 – CCA
GAG GCC ACT TGT GTA GC – 39.; Primer 7 (ON30) : 59 –
GTC CGA AGA ACG GAT CCA AGC TTA TGC – 39. A
combination of primers OF165 and OF166 amplifies a band of
458 bp on the wild-type DNA, a band of 520 bp corresponding to
the Fat1Fln allele, and no product from the Fat1DTM allele. The
Fat1DTM allele is recognised by a 305 bp product obtained with a
combination of OF165 and ON30 primers. The neo cassette can
be removed using FRT/Flp recombination (performed with
ActFlpe mice, official name Tg(ACTFLPe)9205Dym [92]), gener-
ating a new conditional allele referred to as Fat1Flox. The Fat1Fln
and Fat1Flox alleles can be recognised from each other using
specific PCR products (For Fat1Fln, the combination of ON17 and
Uni primer yields a 406 bp product; for Fat1Flox, the combination
of ON17 and ON30 yields a 345 bp PCR product). In the current
study, all the conditional experiments were done using the
Fat1Fln allele. To perform the conditional ablation, of Fat1 in
Pax3-cre-derived tissues, we mated Fat1Fln/Fln mice with Pax3cre/+
mice. Because of our observation of female germline activity of the
Pax3-cre line, we exclusively selected Fat1Fln/+; Pax3cre/+ males to
perform crosses with Fat1Fln/+ or Fat1Fln/Fln females (also carrying
the MLC3F-2E transgene) to produce conditional embryos.
Human tissue collection
Human Tissues samples were obtained from abortus cases (see
ethics statement) after termination of pregnancy, decided after late
prenatal diagnosis (of FSHD1 or of non muscular medical
symptoms for control cases). The cases used, and their respective
stages are described in Figure S8A. Four cases of foetuses
diagnosed with FSHD were used (Figure S8A) referred to as F1,
F2, F3 and F4, respectively. Family history included in the F1 case
early-onset and severe FSHD phenotypes in a sibship carrying the
same haplotype (family tree shown in Figure S8D). In the she
second (F2) and third (F3 and F4, twin foetuses) cases one parent
had FSHD. FSHD diagnosis was characterized by standard
procedures involving southern blotting using a combination of
restriction enzymes and probes, to characterize contraction status,
10 versus 4 chromosome, and haplotype. The p13E-11 probe was
used on genomic DNA digested with EcoRI alone or with EcoRI
and BlnI, hence determining D4Z4 array length and distinguish-
ing and 4q contractions from 10q contractions [93]. Molecular
combing is then performed with a combination of probes
(including those for D4Z4, the p13E-11, qA and qB-specific
probes, and 10q versus 4q specific) allowing to distinguish
simultaneously 10q from 4q as well as qA from qB haplotypes
and the degree of contraction [94] (see also simplified probe set in
Figure S14B–E). Control biopsies (Figure S14A) were also
obtained from abortus cases, for which termination of pregnancy
was performed on the basis of medical diagnosis different from
FSHD or other muscle related diseases. Detailed information on
clinical and genetic diagnostic for the patients used for CGH and
qPCR studies is provided in the Table S1.
X-gal staining, immunohistochemistry, antibodies
X-gal staining was performed using classical procedures on
embryos or postnatal tissues previously fixed in paraformaldehyde
(PFA) 4% (time depending on strength of lacZ expression), rinsed
in PBS, and incubated in X-gal in combination with potassium
ferri- and ferro-cyanide (FeCN). Staining was terminated by
rinsing in PBS, and post-fixing in PFA4%. Embryos were
transferred in 100% glycerol for imaging and counting dispersed
myoblasts.
For adult murine tissues, anaesthetized mice were perfused with
PFA 4% in phosphate buffer saline (PBS) prior to dissection. Shoulder
belt muscles were carefully dissected under a stereomicroscope, rinsed
in PBS, shortly incubated with fluorescent alpha-Bungarotoxin to
visualise neuromuscular junctions. When necessary, observation
under fluorescence was used to visualise and sub-dissect zones
enriched in neuromuscular junctions. Samples were cryoprotected in
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25% sucrose (in PBS), embedded in a mix with 7.5% gelatine and
15% sucrose in PBS, and frozen for cryostat sections.
Immunofluorescence was performed using primary antibodies
to neurofilament (NF-M, Ab1789, Chemicon), tau (AbCAM),
laminin (Sigma), alpha-actinin (Clone EA-53, Sigma), Ryanodine
Receptor RyR1 (MA3-925, Thermo scientific), Dyhydropyridine
Receptor alpha 1S (MA3-920, Thermo scientific), rabbit anti-
GFP (invitrogen). Antibodies against FAT1 were the following:
two rabbit polyclonal antibodies raised against human FAT1,
HPA001869, HPA023882 from SIGMA (epitopes described in
the human protein Atlas (http://www.proteinatlas.org) recog-
nised two regions of the extracellular domain of FAT1 indicated
FAT1-1869 and FAT1-23882, respectively, in Figure 2A, B. Two
antibodies against the intracellular domain of mouse FAT1 were
used: Fat1-ICD from ref [35], and an additional anti-Fat1 rabbit
antisera (Rb1465) we raised against a GST-fusion protein
encompassing the intracellular domain of mouse FAT1 (see
complete procedure below). Secondary antibodies used were
Cy3- or Cy5-conjugated (Jackson Immunoresearch) or conjugat-
ed with Alexa-488 or Alexa-555 (Invitrogen). NMJs were
visualised with Alexa-488 conjugated alpha-Bungarotoxin (1/
2000), and F-actin with alexa-594 or Alexa-647 conjugated-
Phalloidin (Invitrogen). Retinal vasculature was visualised with
Alexa-488-conjugated GS-IB4 (Invitrogen), as described [83],
including CaCl2 1 mM and MgCl2 1 mM in all incubating
solutions. Image acquisition was performed with a Zeiss Axioplan
equipped with Apotome.
Ultrastructure studies
For electron microscopy analysis, muscles were dissected from
mice previously perfused in 4% PFA, and post-fixed in 2% PFA,
2.5% glutaraldehyde, 50 mM CaCl2 in 0.1 M cacodylate buffer
(pH 7.4). Muscles were additionally postfixed with 1% OsO4,
0.1M cacodylate buffer (pH 7.4) for 2 h at 4uC and dehydrated in
a graded series of ethanol, with a 2h incubation step with 2%
uranyl acetate in 70% Ethanol at 4uC. Samples were further
dehydrated and embedded in epon resin. Thin (70-nm) sections
were stained with uranyl acetate and lead citrate and examined by
transmission electron microscope (Zeiss EM 912). Images were
acquired with a digital camera Gatan Bioscan 792, using the
Digital Micrograph software.
In situ hybridizations and measurement of myoblast
orientation
Embryos were collected in PBS and fixed in 4% PFA. In situ
hybridizations were performed with a MyoD RNA probe on
whole mount E12.5 embryos, according to previously published
procedures [95]. In order to assess the orientation of myoblasts,
the CM muscle sheet was dissected and flat mounted, after
completion of the ISH procedure, for high magnification imaging
with a Zeiss Axioplan. For each muscle, three areas in stereotyped
positions of the CM (3 positions in which the main chain direction
made a 10u, 45u, and 70u angle with the DV axis, respectively)
were imaged at 63X resolution. Scoring myoblast direction was
done using AxioVision image software (Zeiss Imaging). For each
picture, three to four chains were outlined. For each cell, an angle
between the closest outlined chain and the nucleus direction was
measured. Every cell for which the nucleus was visible was
assigned such an angle. The distribution of angles was thus
determined for each embryo side (two CM muscles per embryo),
by defining angle ranges of 10u, and determining the percentage of
cells showing an angle in the given angle range. This distribution
was averaged between 3 wild types embryos sides (n = 3), and 5
Fat1LacZ/LacZ embryo sides (n = 5).
Western blot analysis
Tissue extracts were prepared in EBM buffer (20 mM Tris–HCl
pH 7.5, 150 mM NaCl, 1% Triton, 5 mM EDTA, 5 mM EGTA,
10% glycerol) supplemented with protease inhibitors [95]. To
enrich the lysates in membrane associated proteins, lysates were
lectin-purified by incubation with Lectin-sepharose beads. For
immunoblotting, 50 mg of protein extracts were separated by
SDS–PAGE using 3–8% gradient gels (Invitrogen), blotted onto
nitrocellulose membrane and detected with specific antibodies.
Immunoblots were revealed by ECL (Amersham).
Anti-FAT1 antisera production and purification
We first constructed a GST-FAT1 fusion protein, containing
the C-terminal part of the intracellular domain of mouse FAT1
(from aa 4451 to 4588; an epitope entirely contained by exon 28,
and comprising approximately one third of the cytoplasmic
domain), in PGEX2 vector. Serum was collected from two rabbits
immunized with the GST-FAT1 fusion protein (Rb 1465 and
1464). Antibodies were affinity purified from the two antisera,
using the same GST-FAT1 (GST-Fat1-aa4451-4588) fusion
protein, loaded on Affi-gel 15 support in poly-prep chromatogra-
phy columns, following the manufacturer’s instruction (Biorad).
RNA extraction and Real-Time quantitative Polymerase
Chain Reaction (RT-PCR)
In both mouse and human samples, total RNA was isolated
using Trizol reagent (Gibco, BRL). RNA was resuspended in
100 ml DEPC-treated H2O and quantified by spectrophotometry;
samples used for RT-PCRs had a 260/280 absorbance ratio
greater than 1.8. cDNA was synthesized from 1 mg of total RNA
using Superscript III (Invitrogen) or the First Strand cDNA
Synthesis Kit (Fermentas RevertAid: K1622) and random
oligonucleotides.
In mouse RNA samples, expression levels of Fat1, Creatine kinase B
(CKB) or HPRT were determined by semi-quantitative and/or
quantitative RT-PCRs using real-time sybrgreen PCR assay (life
technologies), using the following primer sets. Fat1 Primer set exons
20–21 (product size: 511 or 525 bp), 59 CCA CGC GGT TGT
CAT GTA CG 39 (exon 20-Fw), and 59 TCC AGT AGG CGA
GGG ATTGC 39 (exon 21-rev). Fat1 Primer set exon 6–8 (product
size: 545): 59 AAG CCC CTT GATGCA GAA CA 39 (exon6-Fw);
59 TCA GCG TTC CTC CCT TTG TC 39 (exon8-rev). Fat1
primer set exons 24–25 (product size 142 bp) 59 TGC TGT CTG
TCA GTG TGA CTC AGG C 39 (exon 24-Fw); 59 GAG AGG
CAT CCT CAC AGT GCT TCC C 39 (exon 25-rev); Fat1 primer
set exons 26–28 (product size varies according to splice variants
expressed; 3 products are observed:268 bp, 304 bp; and 330 bp) 59
CGC TTA GCT CCT TCC AGT CAG AGT CC 39 (exon 26-
Fw); 59 GGG TGG GTG TAT GGA CTC GAA CTG G 39 (exon
28-Rev); HPRT primer set: HPRT-fw: 59 CAC AGG ACT AGA
ACA CCT GC 39 HPRT-rev: 59 GCT GGT GAA AAG GAC
CTCT 39. Creatine kinase B-type (CKB); CKB-Fw: 59ACGACCACT
TCC TCT TCG ATA A 39; CKB-rev: 59 TTT TCA GTG TCA
GCAACAGCT T 39. For qPCR experiments, theHPRT gene was
used as endogenous reference gene to normalize the data across all
samples. For each gene examined, primers were chosen at the
junction between two exons, to distinguish by their size the RT-
PCR products from the genomic DNA PCR products. For Fat1
primer sets, sizes expected from genomic PCR amplicons, in case of
genomic DNA contamination, have been indicated on Figures S4
and Figures S5).
Expression of the human FAT1 gene was monitored by a real
time quantitative RT-PCR method using TaqMan gene expression
Deregulated FAT1 Expression as a Model of FSHD
PLOS Genetics | www.plosgenetics.org 22 June 2013 | Volume 9 | Issue 6 | e1003550
assay reference number Hs00170627_m1 targeting the 59 part of
the FAT1 sequence (Applied biosystem), or using real-time sybr-
green PCR assay (Roche) (see primers below). The ubiquitous beta-
glucuronidase (GUS), was used as endogenous reference gene to
normalize the data across all samples. FAT1 primers were chosen at
the exon2-3 junction: forward primer: 59- CAT TAG AGA TGG
CTC TGG CG-39; reverse primer: 59- ATG GGA GGT CGA
TTC ACG-39). (Fw GUS: 59-CTC ATT TGG AAT TTT GCC
GAT T-39; Rev GUS: 59- CCG AGT GAA GAT CCC CTT TTT
A-39). Primers used for other muscle genes: DHPR-Fw: 59- CGC
AAC TGGTGGGTT GCC AGC-39; DHPR-Rev: 59- GGC CCA
TCC TCC AGC AAC GC -39; MURF1-Fw: 59- CTT GAC TGC
CAA GCA ACT CA -39; MURF1-Rev: 59- CAA AGC CCT GCT
CTG TCT TC -39; DYSF-Fw: 59- GAA GCC AAG GTC CCA
CTC CGA -39; DYSF-Rev: 59- CAG GCA GCGGTG TGT AGG
ACA -39; Calp3-Fw: 59- TCT CTT CAC CAT TGG CTT CGC -
39; Calp3-Rev: 59- TGCTGCTTGTTCCCGTGC -39; B2M-Fw:
59- CTC TCTTTCTGGCCTGGAGG -39; B2M-Rev: 59- TGC
TGG ATG ACG TGA GTA AAC C -39; cSARC-Fw: 59- CGA
CCC GTT TCA AGA CCT TA-39; cSARC-Rev: 59- CCT CAA
TTT TCC CAG CGT GA -39. Similar results were obtained with
two other normalizing genes (b-2-microglobulin (B2M) or the human
acidic ribosomal phosphosprotein (PO)).
Each experiment was performed in triplicate and repeated at
least three times against age matched unaffected foetuses used as
controls (see Figure S6A). For quantitative RT-PCR experiments,
relative quantities of RNA expression were calculated using the
comparative cycle threshold (DDCt) method [96] and were
normalized with GUS RNA levels as endogenous reference gene.
Briefly, the fold change of RNA expression levels was calculated by
the equation 22DDCt, where Ct is the cycle threshold. The cycle
threshold (Ct) is defined as the number of cycles required for the
fluorescent signal to cross the threshold in qPCR. DCt was
calculated by subtracting the Ct values of the endogenous control
(GUS) from the Ct values of the RNA of interest (FAT1 or control
muscle genes, such as DHPR, MURF1, DYSF, Calp3, c-Sarcoglycan).
DDCt was then calculated by subtracting DCt of the sample used
as control from the DCt of FSHD biopsies.
Repression of FAT1 by DUX4-fl
Human primary myoblasts unaffected by muscle disease were
infected with lentivirus carrying either DUX4-fl or GFP as control
for 24 hr. RNA was extracted with Qiagen RNeasy kit, DNAse’d
with Ambion Turbo DNAse and reverse transcribed with
Invitrogen SuperScript III according to manufacturers’ instruc-
tions. Real time quantitative PCR was performed with the
following primers: FAT1-f 59 – GGA AAG CCT GTC TGA
AGT GC - 39; FAT1-r 59 – TGT ATG TCC GGC AGA GGA
AC -39; RPL13a-f 59 – AAC CTC CTC CTT TTC CAA GC - 39;
RPL13a-r 59 – GCA GTA CCT GTT TAG CCA CGA - 39. FAT1
values were normalized to the internal standard RPL13a and
expressed as percent relative to control condition.
Chromatin immunoprecipitation assay
ChIP assays were performed on chromatin from fetal muscle
biopsies (tissue samples obtained as described above) using the
Magna A ChIP kit (Millipore/Upstate). For chromatin prepara-
tion, muscle samples (,50 mg) were weighed, cut in small pieces,
and cross-linked with 1.5% paraformaldehyde for 10 minutes, the
cross-linking reaction being stopped by addition of glycin. Nuclei
were extracted from the tissue samples by using a 2 ml dounce
tissue grinder and the kit’s cell lysis buffer. Chromatin was then
sheared by sonication and quantified after DNA extraction.
Immunoprecipitations were performed on 5 mg of Chromatin,
with 3 mg of the following antibodies: anti-H3K4me3 (17–614,
Millipore), anti-H3K27me3 (07–449, Millipore), and anti-
H3K4me1 (ab8895, Abcam), following the ChIP kit instructions,
using _proteinA-conjugated mareferredbeads. Immunoprecipi-
taded material was then washed, cross linking was reversed with
proteinase K at 56u for 2 h, and DNA was extracted. The
presence of individual regulatory regions in immunoprecipitated
chromatin was analyzed by qPCR using sybr green (Invitrogen) on
a Biorad CFX96 apparatus. Relative quantities of each chromatin
bound fragment expression were calculated using the comparative
cycle threshold (DDCt) method again [96] and were normalized
either relative to the amount of input DNA (in the same amount of
chromatin before immunoprecipitation, quantified with the same
PCR), or with levels of the promoter region of a normalizing genes
GUSB.
Oligonucleotides for FAT1 Promoter are: FAT1_P1_Fw: 59
CTT AAG TTT GCC CTG GTC GGA AGC C 39;
FAT1_P1_Rev: 59 AAA GTC CTC GGC AGC TCC GTG
ATC C 39; Oligonucleotides for the 17/18 intronic enhancer
were: FAT1_inton17_Fw: 59 gga gtg ggg agg agg gaa gag tgg g 39;
FAT1_intron_Rev: 5 ctt ccc tct tgc tct tct tct agc c 39. Primers for
the normalizing GUSB promoter were: GUSB_E/P_Fw: 59 AGA
GGA TGT AGA CCA GGC AAA AGC C 39; GUSB_E/P_Rev:
59 TAG AGG ACA GGA CAT GAC ATC AGG C-39. All
sequences were selected based on the Encode ChIP tracks on the
UCSC browser (available with the base genome Human Mar.
2006 (NCBI36/hg18)).
Genomic DNA array screen for microdeletions in FSHD
patients
DNA was hybridized on a Nimblegen HD2.1 genomic array
consisting of 135,000 probes targeting the 4q35.2 genomic region.
Probes were designed with a spacing of 10 bp between con-
secutives probes in the exonic/intronic regions and 100 bp in the
intergenic regions. Labeling of DNA and hybridization was based
on the Nimblegen protocols. Arrays were scanned with the MS200
scanner (Roche) and the acquired paired files were analyzed using
the CGHweb algorithms [97]. To visualize the deletion/duplica-
tion events, coordinates were formatted as a bed file and added in
the custom tracks of the genome browser (genome.ucsc.edu).
Patients that had CNVs in the intron 16–17 area are refered to
with the number corresponding to their number in the patient
summary table (Table S1).
A first PCR validation was performed using primers flanking the
deleted area. This approach is expected to yield a PCR product of
approximately 1500 bp from a control locus, and a smaller size
product in the case of the deleted allele, the deletions being
approximately 1 kb long. Primer sequences are: Del-Fw: 59- CCT
TCA CCT GCA GTA AG-39; Del-Rev: 59- CTA GGA TTC
CTA AGA GC -39. This approach led to validate the presence of
both the 1500 band and the smaller band in the three independent
patients (numbers 11, 12 and 25), plus patient 13 (sibling of 12), as
carrying a deleted allele as well. Moreover, 20 unaffected controls
were tested with this method and only yielded the control 1500 bp
band, indicating the absence of deleted alleles.
Further validation of the deletion was performed by quantitative
PCR, comparing the relative amount of PCR products scanning
the deleted area, using as reference a PCR product outside the
considered zone, a method used to quantify copy number
variations [96,98]. All DNA samples, whether from healthy
controls or from FSHD patients, were normalized with the
ADORA Reference PCR, against one healthy control DNA used
as standard DNA (set to 100%). The reference primers are as
follows: chr17p12 : ADORA2B-2F: 59-GTC ACT CTT TTC
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CAG CCA GC-39 ; ADORA2B-2R:59-AAG TCT CGG TTC
CGG TAA GC – 39. The primers corresponding to the deleted
area were as follows: qPCR-primer-1: 59 – GCA ACA GAG GCC
AAT GGA AA – 39; qPCR-primer-2: 59 – CTG AAA AGA TTT
CAG GTT ACA CGC T – 39; qPCR-primer-3: 59 – TTC GGT
AAG ATG GGA GCA GCC TTC C - 39; qPCR-primer-4: 59 –
GGT CCT GAC AAG CTA ATC CTG AGG G - 39; qPCR-
primer-5: 59 – GGA GTG TGG TGT GTT CTA GGT TAT
GG – 39; qPCR-primer-6: 59 – AGC AGA CAA GAG CAC AAG
GCA TTT C – 39; qPCR-primer-7: 59 – GGA ACA CAG CCA
AAT CTA TAT GGG – 39; qPCR-primer-8: 59 – TCT TCC
TCC TCA CAC TCC CTT TC – 39; qPCR-primer-9: 59 – CCT
GGG CAA TGA GTG TAA CTC C – 39; qPCR-primer-10: 59 –
CCA ACC TCC TCC CTA CTC CAC TT -39; qPCR-primer-
11: 59 – CCA GTG GCA GCA GGT CTG ATT AAG C - 39;
qPCR-primer-12: 59 – GGG AAA CGT AGA ATT CAA GAA
GTC GC - 39 (primers numbered as in Figure 10A and Figure
S16A).
Assay of hypomethylation status at D4Z4 repeats
Among contraction-independent cases, a large proportion,
referred to as FSHD2, harbours hypomethylated D4Z4 [63–64],
while others do not and are expected to carry unrelated causal
abnormalities. Hypomethylation was assessed for 8 patients as
indicated in the patient summary table, by digesting genomic
DNA, with BlnI, CpoI and Eco91I, and hybridizing the southern
blot with the p13E-11 probe, as described [64]. Numbers
indicated represent the percentage of methylated proximal D4Z4
unit at chromosome 4q35.
Statistical analysis
Results were expressed as the mean 6 s.e.m. Statistically
significant differences were assessed by unpaired t-Student test, or
Mann-whitney test for non-Normally distributed data, X2 test or
Fischer tests (for linkage studies), calculated with the StatEL add-in
program to excel. The Kaplan-Meier plot was made with the
StatEL add-in program to excel, and P value was calculated with
the logrank test. * indicates P value,0.05; ** indicates P
value,0.001.
Supporting Information
Figure S1 Fat1-LacZ expression. (A) Fat1LacZ/+ E10.5; E11.5 and
E12.5 embryos stained with X-Gal to reveal b-galactosidase
activity. The dotted areas are magnified in Figure 1C. The hotspot
of expression in/around the Cutaneous Maximus (CM) is
indicated with a red arrow. (B) LacZ expression in Fat1LacZ/+
embryos faithfully reproduces Fat1 expression as seen by in situ
hybridization on transverse sections of E12.5 embryos in
equivalent positions (upper thoracic). Positions of the CM,
Latissimus Dorsi (LD) and Trapeze. (C) X-Gal staining of an E12.5
embryo carrying the MLC3F-2E (LacZ) transgene, showing the
pattern of muscle differenciation.
(TIF)
Figure S2 Myoblast orientation phenotypes in non-CM scapular
belt muscles of Fat1LacZ/LacZ embryos. Whole mount in situ
hybridization with a MyoD RNA probe on wild type (A, C, E) or
Fat1LacZ/LacZ (B, D, F) E12.5 embryo. (A, B) Low power
magnification micrographs showing a side view of shoulder area.
Anterior is to the left, dorsal is to the top. (C, D) Higher power
magnification micrographs showing an enlargement of the
corresponding boxed areas in (A and B), respectively. Fat1LacZ/
LacZ embryos present numerous dispersed myoblasts in ectopic
positions in the shoulder area, either as individual cells (red
arrows), or clustered and forming ectopic muscles (orange arrows).
(E, F) Higher (x63) magnification views of the corresponding
boxed areas within the trapezius muscles in (C and D) showing
misoriented myoblasts in Fat1LacZ/LacZ embryos. Scale bars: (A–B)
0.5 mm; (C, D) 50 mm; (E, F) 10 mm.
(TIF)
Figure S3 Targeted conditional deletion of FAT1 transmem-
brane domain. (A) Strategy used to generate the conditional allele.
1- Top: genomic organization of the Fat1 locus around the
targeted area. 2- Targeted Fat1 locus, in which exons 24 and 25
(the latter containing the transmembrane domain) were flanked by
LoxP sites (Fat1Fln allele). The locus also contains a pgk-neo
selection cassette, itself flanked by LoxP sites (yellow triangles) and
by FRT sites (blue triangles, for later removal of the pgk-neo cassette
only). An external probe (red bar) was used to identify
recombinant ES clones by Southern blotting. The sizes of the
NcoI restriction fragments are indicated.3- Neo cassette removal is
permitted by FRT-mediated excision of the neo cassette, which is
flanked with both FRT (blue) and LoxP (yellow) sites. This
generates a Fat1Flox allele, in which exons 24–25 are flanked on
the 59 side with one LoxP site, and on the 39 side with one leftover
FRT site, followed with a LoxP site. 4- CRE-Recombined Fat1
locus: Genomic organisation of the targeted Fat1 locus after cre-
mediated excision of the entire fragment comprised between loxP
sites, including exons 24–25 and the neo cassette. This new
recombined allele is referred to as Fat1DTM allele. Primers
indicated (1 to 7) are the ones used for genotyping by PCR. ES
screening primers are given in the method section. (B) Abnormal
shape of the Cutaneous Maximus in Fat1DTM/DTM embryos. Flat
mounted preparations of dissected skeletal muscle groups from
E13.5 and E18.5 control and Fat1DTM/DTM embryos, carrying the
MLC3f-2E transgene, in which differentiated skeletal muscle cells
are revealed by X-gal staining. Analysis of skeletal muscles
confirms the reduced and misshaped CM at E13.5. The MLC3F
transgene also reveals the presence of disoriented muscle cells in
the forming CM at higher magnification. The shape of CM from
E18.5 embryos is shown on the right. (C) Kaplan-Meier plot
showing the probability of survival of Fat1DTM/DTM mice. Most
(70%) Fat1DTM/DTM mice die between postnatal days P0 and P1,
and less than 15% of Fat1DTM/DTM mice survive beyond 3 months
after birth.
(TIF)
Figure S4 Selective and asymmetric muscle shape abnormalities
in E14.5 Fat1DTM/DTM embryos. Skeletal muscle groups were
visualized in E14.5, wild type and Fat1DTM/DTM embryos carrying
the MLC3f-2E (LacZ) transgene, by X-gal staining. (A) Low
magnification images showing the entire embryos. The drastically
reduced length and density of the CM muscle is also visible at that
stage. (B) high magnification views of hindlimb shank muscula-
tures, showing no obvious shape differences, in particular in the
tibialis anterior muscles, at that stage. Muscle name abbreviations:
bf: biceps femoris; CM: cutaneous maximus; edl: extensor digitorum longus;
pd: peroneus digitorum; pl: peroneus longus; ta: tibialis anterior. (C)
Illustration of asymmetry of muscle shape abnormalities observed
in two Fat1DTM/DTM embryos, by showing their respective left and
right sides. All red arrows point to shape abnormalities that are
different between the two sides.
(TIF)
Figure S5 Residual expression of Fat1 RNAs in the Fat1LacZ/LacZ
hypomorphic allele. In the Fat1LacZ insertion allele (ES line name
Fat1KST249), multiple copies of a secretory-trap vector [41–42] were
inserted in tandem downstream of the first exon of the Fat1 gene
(Figure S3A). As a result, the main product of the Fat1 locus is a
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fusion protein of 291 kDa, including the first exon of Fat1 (the first
8 cadherin domains), in frame with the exogenous transmembrane
and beta-geo fusion protein (Figure S2A). (A, top) Schematic
representation of the gene trap vector and its insertion point in the
mouse Fat1 locus. Precise content of the gene-trap vector has been
described previously [41–42]. With its splice acceptor site, the
depicted cassette behaves as an exon. Following (in blue), is an
element encoding a transmembrane domain, and a beta-geo
fusion reporter (in frame fusion of the b-galactosidase and the
neomycin resistance gene). The ES selection procedure ensures
that this reporter cassette is in frame with the preceding exon (exon
1 of mouse FAT1). The resulting FAT1-b-gal fusion is a
transmembrane protein depicted in Figure 2A. This protein is
recognized by antibodies raised against an epitope of FAT1
mapping in exon 1 (Fat1-1869; Figure 2B), but not by an antibody
raised against a downstream epitope in the extracellular domain
(Fat1-23882; Figure 2B). (A, bottom) Representation of several
possible RNA products of the Fat1 gene in mouse as they appear
proposed by Ensembl as Ensembl-Havana and as EST-based gene
products, respectively. At least three alternative sites of transcrip-
tion initiation were identified, two of which located downstream of
KST249 integration site. (B) RT-PCR analysis of Fat1 transcripts
in wild type and Fat1LacZ/LacZ mice, using primers matching exons
6–8 of mouse Fat1, and HPRT as control RNA. RT-PCRs were
performed on RNA extracted from kidneys. mRNA containing
Fat1 exons 6–8 in kidneys are absent in adult Fat1LacZ/LacZ mice
compared to control. (C) RT-PCR analysis of Fat1 transcripts in
wild type and Fat1LacZ/LacZ mice, using primers matching exon 20-
21 junction of mouse Fat1, Creatine kinase b (CKB), and HPRT as
control RNA. RT-PCRs were performed on RNA extracted from
rhomboid and CM muscles. Residual Fat1 mRNA levels containing
exons 21–22 in Fat1LacZ/LacZ mice inversely correlate with
phenotype severity. In all cases, primers were chosen in two
consecutive exons, so that the size of the amplicon resulting from
cDNA and from any potential genomic DNA contamination
would result different (sizes indicated). The band sizes shown are
those resulting from cDNA amplification, and cannot be genomic
DNA contamination. Animals used for RNA extractions were 10
week old littermates, a wild type mouse of 23 g, and 2 cases of
Fat1LacZ/LacZ mice: one presymptomatic (with only slightly reduced
weight as compared to wild type (20.4 g)), and one with strongly
impaired growth and with 15% weight loss (11 g when sacrificed).
Levels of residual Fat1 RNA differ between Fat1LacZ/LacZ mice, but
also between muscles in a given mouse. The lowest levels of Fat1
correlate with the most severe phenotype, as assessed by body
weight, or by levels of CKB, known to be elevated in dystrophic
muscles. (D) In situ hybridization with an RNA probe corre-
sponding to the 39UTR of Fat1 on whole mount spinal cords from
E12.5 Fat1LacZ/+ (left) and Fat1LacZ/LacZ (right) embryos. Results
show that Fat1 RNA levels are reduced in most but not all cells
within the Fat1-expression domain.
(TIF)
Figure S6 Specific muscle wasting in presymptomatic Fat1LacZ/
LacZ mice turns to generalized muscle wasting in symptomatic
Fat1LacZ/LacZ mice. (A) Kaplan-Meier plot showing the relationship
between disease span and age of onset, as evidenced through the
comparison of the probability of onset (blue curve: probability of
being presymptomatic) with the survival curve (probability of
survival), on the same set of 49 Fat1LacZ/LacZ mice. Fat1LacZ/LacZ
mice with early onset show short disease span, while the disease
span can be long for mice with late onset. (B) Extent of muscle
wasting in adult Fat1LacZ/LacZ mice at presymptomatic and
symptomatic stages of phenotype progression. Muscle dissection
in adult wild type (B1,4) and Fat1
LacZ/LacZ mice at presymptomatic
(B2,5) or advanced symptomatic (B3,6; 28% weight loss) stages
reveals a pronounced reduction in volume and thickness of the
CM muscle at both stages, while Gastrocnemius muscle in the
hindlimb only show pronounced wasting at later stages or
phenotype progression. Because of the tight association with the
skin of its caudal, the CM cannot easily be dissected for weight
measurements. In pictures in B1,2,3, this skin-associated caudal
part was therefore arbitrarily cut, preventing fair assessment of its
true volume. The CM was consequently not included in the
relative muscle mass measurements in Figure 3D and Figure S4
(C). (B7–9) Myofibre diameter within the Gastrocnemius muscle was
visualized on transverse sections from wild type and Fat1LacZ/LacZ
mice at presymptomatic stage (B8) or at advanced symptomatic
stage (B9, 20% weight loss), using antibodies against laminin. (C)
Masses of dissected muscles of Fat1LacZ/LacZ mice at advanced (20–
30% weight loss, n = 3) disease stages relative to age-matched
controls (n = 6; average wild type weight defined as 100%). (D)
Histological section of Cutaneous maximus muscles from adult wild
type and Fat1LacZ/LacZ mice at presymptomatic stage, lightly
stained with Toluidin Blue, showing reduced thickness (top), as
well as reduced myofibre density, reduced myofibre diameter, and
infiltration with connective tissue (bottom, higher magnification).
Scale bars: (B1–6) 4 mm; (B7–9) 50 mm.
(TIF)
Figure S7 Reduced myofiber diameter and cellular infiltrations in
affected muscles from adult Fat1DTM/DTM mice. (A) Cryosections of
the Trapezius Thoracis, Pectoralis Major, Tibialis anterior, and Soleus
muscles from adult wild type and presymptomatic Fat1DTM/DTM
mice (4 months old) were stained with phalloidin-Alexa647 (purple),
anti-Laminin (green), Collagen I (red), and DAPI (blue). The
selected areas illustrate places in the trapezius and Pectoralis Major
muscles with cellular infiltrations (yellow arrows) between myofi-
bres, with two examples (right pictures) of perivascular infiltrations.
In tibialis Anterior, the selected area contains nuclei of infiltrated
cells surrounded with Collagen I-positive deposit (yellow arrow). (B)
Average myofiber diameters were quantified in the analysed
muscles, and presented as %age of the area of the corresponding
Wild type muscle. Myofiber diameter is significantly smaller in
Trapezius (** p,0.001), in Pectoralis Major (** p,0.001), and in
Tibialis anterior (* p,0.01), but not in soleus.
(TIF)
Figure S8 Ectopic muscles variably connecting shoulder or
humeral muscles, which are subject to loss of integrity at adult
stages. Ectopic muscles (Ect.) were identified during dissection of
shoulder or limb musculature from P3 Fat1LacZ/LacZ pups (A–C)
and several adult Fat1LacZ/LacZ mice at presymptomatic (D–I) or
advanced (J–L) stages of disease progression. Each ectopic muscle
was first photographed in its original context (except rhomboids,
where the dissection procedure makes it impossible), to visualise
original attachment sites with other muscles, and at higher
magnification, after dissection pinned on sylgard, without
disconnecting the ectopic muscles from the limb or shoulder
muscles they were connected to. (C, L) Toluidin counterstained
semithin sections of the ectopic muscles seen in (A and B) and (J
and K), respectively. Images show that myofibers properly
assemble the contractile apparatus (C, P3) but display severe
alterations of their histology at adult stages (L). LD: latissimus dorsi;
Trp: trapezius; Tri: triceps brachii; s. sc: subscapularis muscle. Scale bars:
(A) 2 mm; (B) 0,5 mm; (D) 6 mm; (E) 1 mm; (C, F) 20 mm.
(TIF)
Figure S9 Examples of NMJ denervation and atrophy in
Fat1LacZ/LacZ mice. NMJs were visualized in wild type (A1–A3)
and Fat1LacZ/LacZ (B1–D3) rhomboid muscles by immunolabelling
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AChR clusters with a-bungarotoxin (a-BTX, green), and nerve
endings with neurofilaments (NF, red). Each synapse is shown with
separate a–BTX-green (1) and NF-red channels (2) separately, and
with a merge image of both channels (3). In wild type synapses, the
NF-positive axon endplate overlaps with all circumvolutions of the
bretzel-like shaped a-BTX-positive postsynaptic area. A portion of
axon proximal to the NMJ is intensely stained with NF (white stars
in all panels). By contrast, Fat1LacZ/LacZ synapses display reduced a-
BTX-positive surface, with fragmentation, interruptions, swelling,
or absence of the axon endplate, although the NF-positive axon
(white starts) is still detectable.
(TIF)
Figure S10 Tissue-Specificity of Pax3-cre recombinase activity.
(A, B) Pax3-cre activity was assayed by performing anti-YFP
immunohistochemistry (rabbit anti-GFP antibody, Invitrogen) on
cryosections of an E12.5 Pax3cre/+; Rosa26Lox-STOP-Lox-YFP/+ embryo.
(A) Section at Forelimb level, showing muscle masses in the limbs.
The two magnified areas show the limb and spinal cord region. In
the limb, besides its activity in muscles, Pax3-cre also leads to
excision in neural crest derivatives including Schwann cells along
the nerves. In the Spinal cord, Pax3-cre-derived lineage includes
dorsal neural precursors and their derivatives mostly confined
dorsally. Motor neurons in the motor columns do not express YFP,
hence are not part of the Pax3-cre lineage. (B) a slightly posterior
section shows efficiency of Pax3-cre activity in the Cutaneous maximus
muscle. (C) Section of an E12.5 Fat1LacZ/+ embryo stained with X-
gal at a forelimb level comparable to that shown in (A), illustrating
Fat1 expression in the same muscle mass as that expressing YFP in
the magnified area in (A), as well as in a cervical motor neuron
pool, throughout the ventricular zone, and in multiple non muscle
sites, including the vertebral bodies. (D) In situ hybridization was
performed with antisense probes for myoD (top) and for Fat1-
exon24/25 (the floxed exons) on alternate cryostat sections of a
Fat1Fln/Fln and a Fat1Fln/Fln; Pax3cre/+ E12.5 embryos, at a level
slightly posterior to that shown in (B). In contrast to Fat1
expression in the ventral neuroepithelium (vNE) or in the lung,
which is preserved because it does these tissue-types do not derive
from Pax3-expressing precursors, Fat1 expression is reduced or
abolished in Pax3-derived cell types, such as the dorsal
neuroepithelium (dNE) or muscles (CM, LD and spinotrapezius
are indicated).
(TIF)
Figure S11 Fat1 RNA levels are mildly affected by the
conditional strategy. (A) Scheme of the murine Fat1 genomic
locus, showing exon/intron structure, highlighting the area that
has been floxed in the conditional allele, as well as the positions of
primers that have been used for quantitative RT-PCR studies on
mouse tissues. (B,C) RT-PCR studies were performed on RNA
preparations from embryos of the indicated genotypes, to evaluate
the impact of Fat1 targeting on expression of Fat1 mRNAs
containing either the floxed exons (24–25), or the last C-terminal
exons (26 to 28). (B) All PCRs were performed on cDNA
preparations with or without reverse-transcriptases (+ or 2 RT),
and were loaded on agarose gels to validate that the observed
amplicons were specifically obtained from cDNA. In all cases,
since primers were chosen in two different exons, and the sizes
expected from amplicons from cDNA and genomic DNA are
indicated. (C) quantitative PCRs were performed on cDNAs from
wild type, Fat1DTM/+; Fat1DTM/DTM; Fat1Fln/+ and Fat1Fln/Fln
embryos, to measure the relative amount of RNA containing the
floxed exons (24–25, top graph, blue), or the last C-terminal exons
(26 to 28, bottom graph, red). Data for each genotype were
averaged from 3 embryos, and HPRT was used as normalizing
gene. (Top graph): As expected, expression of mRNAs containing
exons 24–25 is abrogated in Fat1DTM/DTM embryos, and reduced
by 50% Fat1DTM/+ in embryos. The presence of a neo cassette in
the conditional Fat1Fln allele exerts a mild effect on Fat1
expression, visible through a 50% reduction of the exon 24–25
signal in Fat1Fln/Fln embryos. (Bottom graph): Expression of
mRNAs containing the last exons is not abrogated by the
constitutive deletion of exons 24–25, and respresents less than
50% in Fat1DTM/DTM embryos compared to wild-type. In contrast
to upstream exons 24–25, expression of RNAs containing exons
26–28 is only moderately influenced by the neo cassette in
Fat1Fln/Fln embryos. This suggests that the lowering observed in
Fat1DTM/DTM embryos is a consequence of loss of Fat1 function
and indicates an autoregulation mechanism.
(TIF)
Figure S12 Fat1 ablation in trunk premigratory muscle
precursors under Pax3-cre reproduces the scapulohumeral muscle
shape phenotypes of the constitutive mutants. Muscle anatomy
was visualized at E14.5 (A, B) and E15.5 (C), by X-Gal staining in
Fat1Fln/Fln; MLC3F-2E and Fat1Fln/Fln; Pax3cre/+; MLC3F-2E
embryos. Mild phenotypes can be detected in Fat1Fln/Fln embryons
in the face (reduced occip. Frontalis muscle, and zygomatics), and
through appearance of misplaced muscle fibres between Trapezius
Cervicalis and Trapezius Thoracis, frequently unilateral or asymmetric
(red arrow). While Pax3-cre driven recombination in Fat1Fln/Fln;
Pax3cre/+; MLC3F-2E embryos does not cause any worsening in
muscle shape and size in the face, abnormalities can be seen in the
scapulohumeral region, such as the appearance of an additional
muscle, in an ectopic position reminiscent of that seen in Fat1DTM/
DTM embryos, without insertion of its extremity between the
spinodeltoid and the Triceps brachii muscles.
(TIF)
Figure S13 Residual FAT1 protein isoforms are produced in
Fat1LacZ/LacZ and Fat1DTM/DTM mice. Residual FAT1 protein levels
in Fat1LacZ/LacZ mice inversely correlate with phenotype severity.
(A) Western blot analysis on Lectin-purified muscle protein
extracts from 9 days old pups, comparing a wild type and two
Fat1LacZ/LacZ cases with different phenotype severity, was per-
formed using a previously characterized anti-FAT1-ICD antibody
from ref [35]. (B, C) Western blot analysis was performed with: (B)
total brain protein lysates from the same cases shown in (A), or
with (C) brain and muscle protein lysates from wild type and
Fat1DTM/DTM P0 pups. Membranes with were blotted with anti-
FAT1 antibodies (Rb-1465). ERKs protein levels were used as
loading controls (lower panels in A and B). Mutant Fat1LacZ/LacZ
mice survive postnatally with variable phenotype severity (see
Figure 3C). In the two examples shown here, both Fat1LacZ/LacZ
mutants showed strong phenotypes since birth including impaired
growth, with a milder case weighing 3.6 g and a severe case
weighing 2.1 g (where reduced weight reflects phenotype)
compared to their wild type littermates weighing 6.5 g in average.
(TIF)
Figure S14 Characteristics of human foetal FSHD1 and control
cases. (A) Tables listing the FSHD1 foetuses (top) and control
fetuses (bottom) from which biopsies were used for the present
study. These tables indicate for each case, the ID symbol, the stage
at which termination of pregnancy was performed (in weeks of
amenorrhea), their sex, and for FSHD1 cases, the number of D4Z4
microsatellite repeats. (B) Scheme representing the design of DNA
probes and fluorophores used for genotyping FSHD patients by
molecular combing, in combed genomic DNA as described in ref
[94]. (C) Molecular combing genotyping results showing 3
different alleles of 4q35 were detected in the genome of one male
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individual, chimaeric carrier of an FSHD1 allele: One 4qB allele
(blue, right side), one ‘‘normal’’ 4qA allele with a long D4Z4 strech
(green), and one contracted 4qA allele (4qA*), qualifying as
FSHD1. This individual was not diagnosed with FSHD, most
likely owing to his degree of chimaerism, but was the father (family
tree shown in (D) of one first child with severe, early onset FSHD,
and one foetus diagnosed with FSHD as well through prenatal
diagnosis (one of which was used in this study as F1;genotype
shown in E). (D) Family tree showing the distribution of FSHD
symptoms in this patient family. (E) Molecular combing genotyp-
ing of the F1 FSHD foetus, showing one 4qA* contracted FSHD1
allele inherited from the father, and one 4qB allele inherited from
the mother (distinct from the father’s 4qB).
(TIF)
Figure S15 qRT-PCR and immunohistochemistry data from
foetal FSHD muscle. (A) Western blot analysis of Fat1 levels in
muscle protein extracts from the 26 weeks old FSHD Foetus with
1.5 D4Z4 repeats (F1) and 2 age-matched control foetuses (C1 and
C2) with the anti-FAT1-ICD antibody from ref [35]. (B) qPCR
analysis of mRNA levels of several genes other than FAT1 (shown
in Figure 7) involved in muscle biology (DHPR, c-sarcoglycan
(cSARC), MURF1, DYSF) in quadriceps muscles of a 26 weeks old
FSHD1 foetus (F1) harbouring 1.5 D4Z4 repeats in the 4q35
region (dark red bars), and a 16 weeks old FSHD1 foetus
harbouring 4.3 D4Z4 repeats at 4q35 region (F2), respectively
compared with age-matched control foetuses (blue bars). (C)
Immunolocalization of FAT1 (Rb-1465 anti FAT1-ICD, green)
and a-actinin (aact, red) in longitudinal sections from human
quadriceps biopsies from a control (top) or and the FSHD1 (F2,
bottom) foetus with 4.3 D4Z4 repeats. (D) Quantitative PCR
shows that DUX4-fl downregulates expression of FAT1 in human
primary myoblasts. DUX4-fl or GFP (control) were expressed in
unaffected muscle cells by lentiviral delivery. Data were normal-
ized to internal standard RPL13a and represented as mean +/
2SD of triplicates with control set at 100%.
(TIF)
Figure S16 Custom array CGH analyses of genome copy
number changes in the 4q35.2 region. (A) Scheme of the genomic
region in which CNVs were identified. The region represented is
identical to that shown in Figure 10. The dotted line boxes
represent positions of the PCR primers used for qPCR validation
of copy number variants. The boxes in grey are those shown in
Figure 10, the brown ones represent position of the primers for
qPCRs shown in (D). (B) Screen copies of USCC browser lanes
matching the position shown in (A), representing ENCODE-
derived data (available on http://genome.ucsc.edu). The ‘‘layered
H3K27Ac track’’, shows enrichment of the H3K27Ac histone
mark across the genome as determined in 7 cell lines by a ChIP-
seq assay (the H3K27Ac histone mark is the acetylation of lysine
27 of the H3 histone protein). The lower tracks represent
expanded image showing a chromatin state segmentation [67]
for each of 7 of the nine human cell types, computationally
integrating ChIP-seq data for nine factors plus input. The intron
16 ehancer appears labelled as exhibiting strong enhancer activity
in HSMM cells (human skeletal myoblast muscle cells). (C)
Genome copy number variation frequencies are plotted as a
function of position in the same region as that shown in (A).
Chromosome locations (NCBI36hg18 build) are indicated by
numbers above graph. Negative values (log2ratio,20.3) indicate
frequencies of probes showing copy number decreases between
DNA of patient 11 respect to a control DNA. The extent of
deletion is of around 1 kilobase. (D) Copy number validation of the
deletion by qPCR. The relative amounts of a PCR fragments
obtained using primers couples indicated in (A), which amplifica-
tion corresponds to the control allele (blue bars), were compared
between a control patient DNA (with 2 copies of the normal allele),
and three C.I.FSHD patients carrying one copy of a deleted allele
(green bars); but also three additional c.i.FSHD patients (orange
bars) that did not show copy number variations in the CGH
experiments. Patients’ numbers refer to the numbers indicated in
Table S1. Data were normalized using an unrelated genomic
fragment (Adora) as internal control. Patients 12 and 13 were both
confirmed, with two Primer sets matching the deletion span
(qPCR (1–2) and qPCR (3–4), corresponding primers shown in A),
to carry half the amount of the normal allele compared to the
control DNA, validating the deletion.
(TIF)
Table S1 Characterization of FSHD patients involved in the
study. Information provided for each patient includes genetic and
clinical characteristics, as well as raw results for each FSHD
patient of qPCR measurement of copy number variants at 6
positions in the FAT1 locus, and of analysis of D4Z4 methylation
(at the CpoI site, proximal repeat, 4q). STATUS indicates whether
the diagnosis was FSHD1 or contraction-independent FSHD
(c.i.FSHD), but also which cases were considered as carrying a
deletion (Loss at any of the 6 positions considered). Patients are
numbered as they appear in Figure 10.
(XLSX)
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